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Methicillin-resistant Staphylococcus aureus (MRSA) infections are often defined 
as healthcare-associated (HA) or community-associated (CA) based on three different 
classification schemes: healthcare risk factor, infection type, or susceptibility pattern.  
This dissertation analyzed the sensitivity, specificity, and utility of these classifications 
using MRSA case data from Michigan. 
MRSA infections were voluntarily reported to the Michigan Department of 
Community Health (MDCH) from October 2004 through December 2005.  Data on 
patient demographics, risk factors, and infection information were recorded on the 
MDCH MRSA Report Form and submitted with laboratory susceptibility test results.  A 
total of 2,151 non-duplicate MRSA infections were reported.  Pulsed-field gel 
electrophoresis (PFGE) tests were conducted on 244 randomly selected isolates from 
reported cases. 
The first project classified MRSA infections as HA or CA using each of the three 
classification schemes, then examined results for inconsistency across methods.  
Comparison of HA and CA results using the common classification schemes revealed a 
large proportion of inconsistent results.  The second project used PFGE test result as a 
gold standard to consider the three classification schemes and other important 
contributing variables aimed at producing an improved multivariable classification 
model.  This new model using infection type, susceptibility pattern, age and hospitalized 




classification method.  The third project evaluated accuracy of the new classification 
model and used it to define the epidemiology of Michigan MRSA infections.  This 
analysis revealed that MRSA is prevalent across Michigan and CA-MRSA, particularly 
among males, blacks, people within correctional facilities, and people presenting to 
emergency departments.  A final project produced a comprehensive review of the first 
seven cases of emergent vancomycin-resistant Staphylococcus aureus (VRSA) in the US.  
All VRSA cases had a history of prior MRSA and enterococcal infection or colonization; 
all had several underlying conditions and most had received vancomycin prior to their 
VRSA infection. 
In conclusion, the improved method to categorize MRSA infections as HA or CA, 
and characterization of the VRSA cases, provides new knowledge that will help to 
accurately target control efforts and prevention methods and messages to better combat 






The Staphylococcus aureus Organism 
 
Staphylococcus aureus is a gram-positive, coagulase-positive, facultatively 
anaerobic, spherical, bacterium that grows singly, in pairs, and irregular clusters.  It is a 
human commensal organism found on the skin and in skin glands, on mucous 
membranes, and in the blood, intestinal, genito-urinary, and upper respiratory tracts.  It 
has the ability to colonize an individual for both short and extended periods of time.  A 
recent study has reported that approximately 29% (78.9 million persons) of the United 
States general population is nasally colonized with S. aureus and about 1.5% (4.1 million 
persons) with methicillin-resistant S. aureus [1].  It is an opportunistic pathogen and has 
long been known as a common cause of human infections.  These infections range from 
minor dermatological conditions to serious systemic illnesses, including small pustules 
(i.e. pimples), furuncles (i.e. boils), folliculitis, impetigo, scalded skin syndrome, 
cellulitis, abscesses, osteomyelitis, endocarditis, pneumonia, meningitis, bacteremia, and 
septicemia. 
History of S. aureus Resistance 
Staphylococcus aureus is a hardy bacterium and also has the ability to develop 
resistance to the drugs commonly used to treat the infections it causes.  Penicillin was 
first introduced in 1940 and its use dramatically reduced the overall number of bacterial 
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infections in the U.S. and worldwide.  However, it was only four years later, in 1944, 
when the first penicillinase-producing strains of S. aureus were reported [2].  By the late 
1940s and early 1950s, most hospital isolates of S. aureus were resistant to penicillin [3].  
In response to this increasing resistance, scientists created a new class of semi-synthetic 
penicillin drugs, which included methicillin.  Methicillin was introduced in 1960, and in 
1961 the first cases of methicillin-resistant Staphylococcus aureus (MRSA) were reported 
from the United Kingdom [4].  Hospitals in the United States were reporting MRSA by 
the mid-1970s.  By the 1990s, MRSA was considered endemic in large urban medical 
centers in the U.S. [5-9].  Vancomycin became the drug of choice to treat the growing 
number of nosocomial MRSA infections, and it continues to be a reliable and effective 
drug for this treatment [10, 11]. 
 As the incidence of MRSA in hospital settings was quickly increasing from the 
mid-1970s through the 1990s, the first reports of MRSA identified in community settings 
were published in the early 1980s [12, 13].  MRSA identified within a healthcare setting 
or among individuals who received recent care from such a setting is referred to as 
healthcare-associated MRSA (HA-MRSA).  MRSA identified among individuals outside 
of a healthcare setting and who have not received recent care from such a setting is 
referred to as community-associated MRSA (CA-MRSA).  The initial reports of CA-
MRSA occurred among injecting drug users.  Reports of CA-MRSA infections remained 
infrequent until 1997, when the deaths of four children in Minnesota and North Dakota 
brought CA-MRSA to national attention [14].  Shortly after this report, the incidence of 
CA-MRSA began increasing throughout the United States.  The increase in CA-MRSA 




its presence.  This new CA-MRSA differed from the more common HA-MRSA in that it 
often occurred among younger individuals who did not have any significant medical 
conditions or occurrences that required recent interactions with a healthcare facility.  As 
CA-MRSA became more prevalent, outbreaks were reported among children attending 
daycare, prison inmates, men who have sex with men, and players of competitive sports 
[15-18]. 
 In 1997, as CA-MRSA reports began increasing, the first clinical case of a HA-
MRSA acquiring intermediate resistance to vancomycin was reported in the United 
States.  This vancomycin-intermediate Staphylococcus aureus (VISA) infection was 
reported in a peritoneal dialysis patient from Michigan [19]. Following this initial case, 
eighteen additional U. S. cases of VISA infection were reported to and confirmed by the 
Centers for Disease Control and Prevention (CDC) through 2006 [20-23].  The prospect 
of vancomycin rendered ineffective for treatment of MRSA infections was of serious 
concern, as it was often the last drug available to treat the highly resistant organisms. 
In June 2002 this fear was realized when a Michigan hospital laboratory and the 
state health department identified and confirmed a hemodialysis patient as the first 
clinical case of vancomycin-resistant Staphylococcus aureus (VRSA) infection in the 
world [24-26].  Through the end of 2006, six additional, epidemiologically unrelated 
cases were reported, one each from Pennsylvania and New York, and four from Michigan 
(Table 1).  In addition to the first case, reports had only been published on the second and 
third cases, with very limited information from the third case [27-30].  Following the full 
report on the first seven VRSA cases [31], two additional cases were identified from 




First Seven U.S. VRSA Cases, 2002-2006 
 
Case Number Date State Risk Factors 
1 June 2002 MI 
 
Hemodialysis 
Chronic Foot Ulcers 
2 Sept. 2002 PA 
 
Morbid obesity 
Chronic foot ulcers 
3 March 2004 NY 
 
Multiple sclerosis 
Long-term care resident 
4 Feb. 2005 MI 
 
Diabetes 
Gangrenous toe wound 
5 Oct. 2005 MI 
 
Morbid obesity 
Post-op wound infection 
6 Dec. 2005 MI 
 
Motor vehicle accident 
Chronic foot ulcers 






Mechanisms of Resistance and Genetic Makeup of MRSA 
 MRSA acquires its resistance via the methicillin resistance gene mecA, which 
encodes a low-affinity penicillin-binding protein PBP2′ (or PBP2a) that is absent in 
susceptible S. aureus strains [32].  This foreign penicillin-binding protein does not bind 
well to most β-lactams, and therefore allows MRSA to grow in their presence.  The mecA 
gene is carried on a mobile genetic element called the staphylococcal chromosomal 
cassette mec (SCCmec).  Five types of SCCmec (I, II, III, IV a and b, V) have been 
characterized, each of which differs in size and genetic composition [33].  SCCmec II is 
one of the larger types and has been associated with HA-MRSA infections, along with 
types I and III.  SCCmec IV is the smallest type and has been associated with CA-MRSA 
infections.  Its shorter length allows for a much quicker doubling time compared to the 
HA-MRSA types [34].  This faster doubling time is thought to be a reason for CA-MRSA 




with other bacteria.  In addition to the mecA gene, some MRSA have the ability to 
acquire resistance genes from plasmids of other resistant organisms.  These acquisitions 
confer multi-resistance to the MRSA organism and often leave only vancomycin and the 
newest available drugs (e.g. linezolid, daptomycin, quinupristin-dalfopristin, tigecycline) 
as effective treatments.  The larger HA-MRSA types are associated with multi-resistance, 
while the shorter CA-MRSA type is usually only resistant to the β-lactams (including 
cephalosporins and carbapenems) [35-37].  In addition to resistance genes, MRSA 
organisms are also known to acquire toxin-producing genes.  CA-MRSA is associated 
with these gene acquisitions, and currently the most common toxin produced by this 
organism is Panton-Valentine leukocidin (PVL) [38].  PVL destroys human leukocytes 
and alone can cause lesions in the skin.  Though MRSA organisms can be very different, 
there is a certain degree of clonality at the molecular level.  In studying chromosomal 
DNA restriction patterns produced by pulsed-field gel electrophoresis (PFGE), the CDC 
has identified a number of clonal USA strains (100-800) that encompass the majority of 
MRSA strains identified in this country [39].  USA strains 100 and 200 are the most 
common associated with HA-MRSA infections and USA strains 300 and 400 are the 
most common associated with CA-MRSA infections [38, 40-42]. 
Mechanisms of Resistance for VISA and VRSA 
 The resistance mechanisms for VISA and VRSA organisms are very different, 
and subsequently a VISA does not become a VRSA along a simple continuum of 
increasing resistance.  The intense selective pressure from the excessive use of 
vancomycin in the treatment of an MRSA infection may cause spontaneous genetic 




these genes are expressed there is a thickening of the cell wall, and a decreased 
peptidoglycan cross-linking as D-alanine binds together in strands.  These changes result 
in a thickened extracellular material that has the ability to sequester vancomycin and hold 
it outside of the bacterial cell wall, thereby reducing the susceptibility of the MRSA to 
vancomycin, and creating a VISA organism [43]. 
 For an MRSA to develop vancomycin resistance, there must be colonization or 
recurrent infections with both MRSA and vancomycin-resistant Enterococcus (VRE), 
often E. faecalis.  In this mechanism, the vanA gene, which mediates resistance in VRE, 
is transferred via a whole plasmid or just the Tn1546 transposon from the VRE to the 
MRSA organism.  It is believed that the pressure from excessive presence of vancomycin 
may play a role in inducing this reaction.  Once the vanA gene is turned on, it produces a 
ligase that cleaves a cell wall precursor.  This resulting change in the bacterial cell wall 
renders it incapable of binding to vancomycin, thereby making the new VRSA 
completely resistant to vancomycin and its effects [26]. 
Epidemiologic and Molecular Differences Between HA-MRSA and CA-MRSA 
 As noted in the discussion on “Mechanisms of Resistance and Genetic Makeup of 
MRSA”, there are many distinguishing differences at the molecular level between HA-
MRSA and CA-MRSA.  In HA-MRSA, the mecA gene is often located on SCCmec II 
and the common strains are identified as USA100 and USA200.  This organism has a 
greater tendency to acquire additional resistance genes, which makes it resistant to more 
classes of antibiotics, including macrolides, aminoglycosides, lincosamides, tetracyclines, 
folate pathway inhibitors, and fluoroquinolones, but it does not acquire toxin-producing 




common strains are identified as USA300 and USA400.  This organism does not have a 
tendency to acquire additional resistance genes, so it is often only resistant to β–lactams.  
However, it does often carry toxin-producing genes, like PVL. 
 There are also epidemiologic differences between these two types of MRSA, in 
addition to the molecular differences.  The risk factors for HA-MRSA and the groups at 
risk are those individuals who have within the past year: been hospitalized, undergone 
surgery, spent time in an intensive care unit (ICU), had an indwelling catheter or medical 
device, are dialysis patients, or reside in a long-term care (LTC) or rehabilitation facility.  
These more resistant infections also tend to be more serious clinically, including surgical 
site, wound, urinary tract, pneumonia, and bloodstream infections.  CA-MRSA has an 
exclusionary definition, that is, the infections aren't associated with the HA-MRSA risk 
groups.  These infections often occur among otherwise healthy individuals and in an 
outpatient setting or within 48 hours after admission to a healthcare facility.  The groups 
at most risk for CA-MRSA include children attending daycare or school, athletes of close 
contact sports, correctional facility inmates, military recruits, homeless individuals, 
injecting drug users, and men who have sex with men.  The risk factors for CA-MRSA 
include close skin-to-skin contact, breaks in skin (cuts, abrasions, skin disease, surgical 
sites), crowded living conditions, poor hygiene, and contaminated items and surfaces.  
These less resistant infections tend to be less serious and are often skin and soft tissue 
infections that may only require incision and drainage without antibiotics.  These minor 
CA-MRSA skin infections are sometimes misidentified as spider bites.  The caveat of 




organism can cause major infections with serious damage, including necrotizing 
pneumonia, severe sepsis, and necrotizing fasciitis [44]. 
Impact of MRSA 
 Infection from a resistant organism increases morbidity and mortality risk for the 
patient as well as healthcare costs.  Compared to a methicillin-susceptible  S. aureus 
(MSSA) infection, MRSA infections are associated with an increase in severity of disease 
(APACHE II Classification System), sometimes requiring additional specialized medical 
treatments (ventilation, surgical debridement, hyperbaric therapy, isolation, etc.), a 
decrease in options for antibiotic therapy that is more costly, often more toxic to the 
patient and sometimes not as effective, an increase in hospital length of stay, and 
sometimes outcomes with debilitating morbidity and even death [45-48].  MRSA 
continues to remain a growing problem, within our healthcare facilities and in our 
communities.  Surveillance data from the CDC National Nosocomial Infections 
Surveillance (NNIS) system report showed that from 1998 through 2002, 45%-52% of S. 
aureus isolates collected from infections in ICU patients were MRSA.  In 2003, 60% of 
those isolates were MRSA, representing an 11% increase in resistance in 2003 compared 
to the mean resistance over the previous five years.  NNIS data from 1998 through 2004 
revealed that of the number of S. aureus isolates tested, the pooled mean percent that 
were MRSA for ICUs was 53%, for Non-ICU inpatient areas was 46%, and for outpatient 
areas was 31% [6].  A recent study of MRSA hospitalizations reported an estimated 
477,927 hospitalizations with a diagnosis of S. aureus infection annually in U.S. 
hospitals.  Of these, approximately 278,203 hospitalizations are related to MRSA. [49].  




an invasive MRSA incidence rate of 19-40/100,000, and a MRSA percentage of S. aureus 
isolates as high as 64% in some hospitals [50]. 
 Michigan antibiogram data indicated an increase in MRSA in Michigan hospitals 
in 2004 compared to 2003, when the statewide mean was 40% and the range across 
regions was 25%-52% [51].  The data collected from hospital laboratories in 2004 
revealed a statewide MRSA percentage of 50%, ranging from 27%-59%.  The southwest 
region of Michigan had higher prevalences (55%-59%) than the northern Lower 
Peninsula and Upper Peninsula of Michigan (27%-33%). 
 MRSA in the community setting has been a growing problem with increasing 
incidence and prevalence in U.S. communities over the past eight years, and studies 
specifically looking at this organism have increased.  Three states (GA, MD, MN) that 
participate in the CDC Active Bacterial Core Surveillance (ABCs) project compared data 
that were collected from 2001-2002 to investigate geographic variability in CA-MRSA, 
demonstrating a range of 8-20% of reported MRSA, and a CA-MRSA incidence range of 
18-26/100,000 [50].  Additional data from the CDC ABCs project, revealed that of the 
invasive MRSA cases reported in 2005 and 2006, about 14% of the cases were 
community-associated (CA-MRSA), 26% were healthcare-associated (HA-MRSA) with 
onset in the hospital, but 60% were healthcare-associated (HA-MRSA) with onset in the 
community [52].  The area most likely to identify invasive CA-MRSA cases was the 
emergency department (ED).  A study collecting data on skin and soft tissue infections in 
adult ED patients from eleven sites throughout the U.S., reported a mean of 59% 
attributable to MRSA, with a range from 15%-74%.  Analysis of these MRSA isolates, 




matched a close variation of this strain, which is the most common CA-MRSA strain in 
the U.S. [53].  The total number of skin and soft tissue infection-related visits to 
ambulatory physicians increased from 8.6 million in 1997 to 14.2 million in 2005 (a 65% 
increase) [54]. 
Impact of VISA and VRSA 
 The infection from a VISA or VRSA organism further increases the morbidity 
and mortality risk and healthcare costs, compared to a MRSA infection.  In addition to 
increased disease severity, there are requirements for specialized medical treatments, 
requirements for isolation precautions and dedicated staff and equipment, length of 
hospital stay increases, and the decrease in options for antibiotic therapy becomes even 
more costly and critical to the patient as well as the community as a whole.  Vancomycin 
is lost as an effective treatment for the infection, when a MRSA organism makes the 
transition to a VISA or VRSA organism.  This impact is critical for two major reasons.  
First, vancomycin is a highly utilized antimicrobial agent and is effective for the 
treatment of a variety of infections.  It is the most effective and reliable drug for 
treatment of HA-MRSA and it remains the drug of choice for these infections.  NNIS 
data from the 2004 report show that vancomycin is ranked most often as the third or 
fourth most utilized antimicrobial agent in nine critical healthcare units and wards, 
including coronary care, cardiothoracic intensive care, hematology/oncology/transplant, 
medical intensive care, medical-surgical intensive care, neurosurgical intensive care, 
surgical intensive care, pediatric intensive care, and non-intensive care inpatient areas [6].  
Vancomycin would be completely lost as an effective antimicrobial agent in healthcare 




comparable to HA-MRSA.  Second, there are very few antimicrobial agents available 
beyond vancomycin that are effective in treating vancomycin-resistant infections.  HA-
MRSA is already multi-resistant to a large number of the older antimicrobial classes.  
The limited list of new agents available to treat vancomycin-resistant infections includes 
only linezolid, quinupristin-dalfopristin, daptomycin, and tigecycline.  These drugs are 
sometimes not tolerated well by patients and issues of toxicity play a role in limiting 
length of therapy.  Resistance to S. aureus has already been reported in three of these four 
antimicrobials and was often acquired within a short time frame of therapy use.  Bringing 
an antibiotic to market from inception to sales is very costly for pharmaceutical 
companies and the incentive for focus on antibiotic production is not prominent.  As a 
result, there is limited research and development being conducted for new antimicrobials, 
and therefore little promise for new antimicrobial agents in the near future.  From 1997-
2006, nineteen VISA cases were reported and confirmed in the U.S., four of these cases 
were identified in Michigan.  From 2002-2006, seven VRSA cases were reported and 
confirmed in the U.S., five of these cases were identified in Michigan.  Two additional 
VRSA cases were identified in Michigan in 2007.  All of the VRSA cases were 
epidemiologically unrelated and have been confirmed by molecular testing to be unique 
organisms. 
Surveillance for MRSA Cases 
 Information about MRSA and the existing differences between HA-MRSA and 
CA-MRSA derives from both data collected through surveillance of these organisms and 
through planned research investigations.  There are only a limited number of population-




MRSA.  The reasons include limited availability of funding, the difficulty in tracking 
large numbers of HA-MRSA in hospitals, and the difficulty identifying CA-MRSA from 
community settings.  There are also those that believe the prevalence of MRSA is too 
high, so it would be impossible to control, and therefore is not beneficial to research any 
further.  In the place of planned studies, analysis of surveillance data can be a very 
effective and efficient way to investigate pathogen characteristics, populations affected, 
risk factors, and behaviors for a specific infection type or disease.  Specific data is 
collected, analyzed, and disseminated through surveillance.  Public health surveillance is 
developed to provide the information needed to control and prevent disease in the 
population.  In order to understand and control communicable diseases, the state health 
department maintains a list of diseases that healthcare providers and laboratories are 
required to report when a case is identified.  The data from these reportable diseases 
allow staff to monitor the health of the community and provide the basis for development 
of education, treatment, prevention, and control efforts.  The CDC’s nationally notifiable 
disease reporting system provides a strong foundation of reporting and surveillance for 
pathogens posing a significant morbidity and mortality threat, providing good descriptive 
data from throughout the nation.  State health departments also maintain reportable 
disease surveillance systems.  Often the lists of diseases include those on the national 
notifiable list, in addition to diseases that may be of specific importance to the population 
of the state and its geographic area.  Unfortunately, MRSA is neither a nationally 
notifiable disease nor a Michigan mandated reportable disease.  The sheer number of HA-
MRSA infections that have been identified in healthcare facilities for many years makes 




A good surveillance system should be simple to use, accepted by those required to report, 
and have a high level of sensitivity for the disease under surveillance [55].  In the case of 
HA-MRSA, these system attributes cannot be met.  It would not be simple, but a very 
difficult process to collect case specific demographics and risk factor data for entry into a 
surveillance system, because of the high numbers of MRSA infections in healthcare 
systems.  This method of surveillance has previously been presented for consideration at 
the both the national and state level, including in Michigan, and has not been accepted by 
the groups that would be required to do this reporting.  In addition, the high prevalence of 
HA-MRSA would mean that many cases would most likely go unidentified and/or 
unreported, and this would greatly reduce the sensitivity of the surveillance system.  The 
definition of CA-MRSA makes it a difficult candidate for surveillance.  CA-MRSA 
occurs in the community, often among mostly healthy individuals.  It would require those 
doing the reporting to be knowledgeable about MRSA and the risk factors of the two 
types, in order to accurately distinguish between HA-MRSA and CA-MRSA and to 
accurately identify the less established community risk factors for the infected individual.  
This would drastically decrease the predictive value positive of the surveillance system 
[55]. 
 The Council of State and Territorial Epidemiologists (CSTE) considered a 
proposal in 2003 to make MRSA a notifiable condition in the U.S., in response to the 
increasing numbers of HA-MRSA infections and the emergence of CA-MRSA [56].  
This would have meant that state health departments would require MRSA data from the 
healthcare providers and laboratories in their jurisdictions via a standardized case report 




need for MRSA surveillance data were discussed at length, it was not passed or adopted 
as a position statement due to the time intensive and costly burden it would have placed 
on those required to report this information.  The final decision that emerged from the 
discussions was that the CDC would require MRSA surveillance from nine of its 
Emerging Infections Program (EIP) sites (CA, CO, CT, GA, MD, MN, NY, OR, TN) 
through the ABCs system.  These sites received considerable funding allowing them to 
conduct surveillance (including for MRSA) that most other state health departments 
could not handle due to lack of resources, staff and money.  The additional 
recommendation was that each state consider conducting its own MRSA surveillance to 
the level and extent possible.  The CDC conducted a survey in 2005 to collect 
information on the status of MRSA surveillance in the states.  Beyond the nine EIP sites, 
little was being done.  Six states (LA, MA, ME, MI, MO, WA) reported aggregate 
antibiogram data, and only a few additional sites reported active/passive MRSA 
surveillance [57].  Recently, there has been an escalation of state legislative mandates 
that will increase the reporting of MRSA in the near future. 
The Michigan Department of Community Health (MDCH) chose to collect 
MRSA data via two methods, in response to the CSTE and CDC recommendations that 
states conduct MRSA surveillance.  Antibiogram data was requested from hospital 
laboratories throughout Michigan beginning in 2002.  These data were aggregated, 
analyzed, and reported yearly.  The information included regional and statewide 
prevalence of MRSA, but was limited by only including a total percent of susceptible 
isolates from all isolates tested in a hospital laboratory.  No specific patient or isolate 




surveillance for MRSA from October 1, 2004 through December 31, 2005 under a 
designated medical research project.  This designation recognized the importance and 
necessity of the data and allowed for its submission to MDCH under HIPAA (Health 
Insurance Portability and Accountability Act) coverage without adding MRSA to the 
permanent Michigan reportable disease list.  The caveat was that this surveillance could 
not be made mandatory under the medical research project designation, so submission of 
information was voluntary.  The purpose was to collect data from both HA-MRSA and 
CA-MRSA infections to help characterize these cases in Michigan, in order to develop 
appropriate intervention and prevention guides, so that transmission and spread could be 
tempered.  [See Appendix for MDCH MRSA Surveillance Case Report Form] 
Surveillance for VISA and VRSA Cases 
 A proposal was also submitted to the CSTE committee to make VRSA infections 
notifiable conditions in the U.S., after the first case was identified in 2002.  This proposal 
was accepted and adopted as a position statement in 2003 [58].  Under this position 
statement, a state would make it mandatory for all VISA and VRSA cases to be reported 
to its state health department and these cases would then be reported to the CDC.  Most 
state health departments adopted this requirement and made these cases reportable from 
the healthcare providers and laboratories within their states.  MDCH followed this 
recommendation and had VISA and VRSA cases added to the reportable disease list in 
Michigan. 
 The burden of reporting these cases is low by number, because only a few cases 
have been identified nationally to date (19 VISA cases and 9 VRSA cases).  It is the 




is necessary, in each case, to evaluate the patient’s defined treatment regimen for 
effectiveness, assess infection control precautions and procedures for appropriateness, 
and conduct an extensive contact investigation to assure no transmission.  There is an 
important need to identify and understand the similarities and differences between these 
cases, because of the significant impact they have on public health.  We need to 
understand the patients’ histories and risk factors, the infection control practices 
surrounding them, and the therapy regimens that have been used to treat their infections, 
in order to prevent future infections from emerging and being transmitted,. 
Future Considerations for MRSA, VISA, and VRSA 
 S. aureus can be found all around us and is a part of our public health history.  
This organism has created mechanisms to evade our antimicrobial agents, since their 
initial discovery.  It will continue to evolve for its own survival.  Based on current 
indications, the incidence and prevalence of MRSA will continue to rise.  The risk groups 
and environments for HA-MRSA and CA-MRSA will intermix and soon the distinctions 
between the two may become blurred.  The current epidemiology must be clearly defined 
and understood, so that the changing epidemiology can be tracked and described 
appropriately.  Without this knowledge, effective intervention and prevention programs 
cannot be developed or implemented.  We need evidence-based educational messages 
and control measures to keep transmission of this organism in check. 
 Although the total number of reported VISA and VRSA cases currently remains 
low, new infections continue to be identified.  The number of cases confirmed in 
Michigan has already raised concern.  The dynamics of these cases must be defined and 




transmission prevented.  The serious threat of losing vancomycin as an effective 
antimicrobial agent increases as the number of VISA and VRSA cases climbs, taking us 
closer to the end of our current antibiotic lifeline. 
Purpose of the Research 
MRSA, VISA, and VRSA infections present differently in communities 
throughout the United States.  It is imperative that a variety of areas continue to conduct 
individual efforts to track and characterize these organisms, in order to control the burden 
that they place on specific individuals, healthcare systems, and communities. 
The research presented in the following chapters utilizes Michigan MRSA 
surveillance data to address the issue of accurately identifying an MRSA infection as 
healthcare- or community-associated, and to appropriately characterize the MRSA 
infections in Michigan and the VRSA infections in the nation.  The investigation in 
Chapter II uses the dataset to evaluate the concordance in classification results when 
MRSA infections are defined as healthcare- or community-associated using three 
preexisting classification schemes.  The analyses in Chapter III use a subset of the 
Michigan MRSA infection data, which have PFGE results available, to identify a more 
accurate model to define MRSA infections as healthcare- or community-associated.  The 
examination in Chapter IV utilizes the newly identified model, and PFGE result when it 
is available, to classify the complete dataset of Michigan MRSA infections as healthcare- 
or community-associated and to present the profile and characterization of these 
Michigan cases.  The report in Chapter V presents the clinical characteristics, 
epidemiologic investigations, infection control evaluations, and microbiologic findings of 




research will provide important information to public health professionals, healthcare 
providers, and researchers for the accurate identification of HA-MRSA, CA-MRSA, and 
VRSA.  This accuracy is pertinent to the effective treatment, appropriate infection control 
strategies, and targeted prevention efforts of these very relevant organisms.  These 
investigations have been approved by the Institutional Review Boards of the Michigan 
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Potential for Misclassification in Defining Methicillin-Resistant Staphylococcus 
aureus Infections as Healthcare- or Community-Associated by Healthcare Risk 
Factor, Infection Type, or Susceptibility Pattern 
 
Abstract 
Background: Healthcare providers and researchers utilize a variety of methods to 
classify methicillin-resistant Staphylococcus aureus (MRSA) infections as either 
healthcare-associated (HA) or community-associated (CA).  The method chosen is often 
dependent upon the information available to them.  The results of that classification may 
dictate patient treatment, infection control recommendations, and prevention efforts.  
This investigation defines MRSA infections reported from throughout Michigan as either 
HA or CA using three common classification schemes: healthcare risk factor, infection 
type, and susceptibility pattern, and then examines the results for 
concordance/discordance across the three classifications. 
Methods: MRSA infections were voluntarily reported in Michigan to the 
Michigan Department of Community Health (MDCH) between October 1, 2004 and 
December 31, 2005.  Data on patient demographics, risk factors, and infection 
information were collected on the MDCH MRSA Surveillance Case Report Form and 
submitted to MDCH with laboratory susceptibility test results.  A total of 2,151 reported 
cases were used in the analyses. 
Results: MRSA infections were first defined as HA or CA, according to each 




pattern.  The demographic, clinical, and microbiologic variables showed similar 
distributions within the HA or CA categorizations among the three classification 
methods.  These results are consistent with previously published literature according to 
the differing presentations of HA- and CA-MRSA.  However, when the HA or CA results 
across the three classification schemes were compared for each case, a large proportion of 
cases (42%) had discordant results. 
Conclusion: This investigation shows that due to the high level of disagreement 
between the classification methods, decisions made for patients and study results are 
dependent upon the method used.  Further research is needed to find a more accurate and 
consistent way to classify MRSA infections, prevalent throughout Michigan and 





Staphylococcus aureus is a human commensal organism and has the ability to 
colonize an individual for short or extended periods of time [1-3].  It is an opportunistic 
pathogen and has long been known as a common cause of human infections.  These 
infections range from minor dermatological conditions like small pustules (i.e. pimples), 
furuncles (i.e. boils), and folliculitis to serious systemic illnesses, like osteomyelitis, 
pneumonia, and bacteremia. 
Methicillin, first introduced in 1960, was one of the earliest antibiotics used to 
treat S. aureus infections in response to growing numbers of S. aureus isolates resistant to 
penicillin.  The first cases of methicillin-resistant S. aureus (MRSA) were reported from 
the United Kingdom shortly thereafter [4].  Hospitals in the United States began reporting 
an increase in MRSA in the mid-1970s.  The incidence of MRSA grew steadily and by 
the 1990s, MRSA was considered endemic in large, urban medical centers in the U.S. [5-
10].  Concurrently, the first reports of MRSA identified in community settings were 
published in the early 1980s [11-14]. 
It became evident, as MRSA case reports increased from both healthcare and 
community settings, that cases occurring in these two distinct settings were different 
epidemiologically.  It was found that these two types of MRSA infections usually occur 
among individuals with different health risk factors and in separate age groups.  They 
present as different types of infections, with varying resistance patterns to therapeutic 
drugs [15-24].  These differences relate to how and why an individual acquires infection, 
their potential for transmission, the seriousness of the infection, consequences to the 




Because of these differences, health professionals have distinguished between these two 
types of MRSA infections by referring to them as either healthcare-associated MRSA 
(HA-MRSA) or community-associated MRSA (CA-MRSA) [27-29]. 
Molecular testing is often used as a gold standard for distinguishing amongst 
MRSA types.  There are, however, three common and less resource intensive ways that 
HA-MRSA and CA-MRSA are differentiated: by healthcare risk factor, infection type, 
and susceptibility pattern [30-38].  These three classification schemes are used by 
healthcare providers and researchers and have proven useful in categorizing MRSA 
infections as HA-MRSA or CA-MRSA for both patients and study participants [27, 39-
50].  Healthcare risk factor may be the most preferred classification method, however this 
information is the most difficult to collect with a high level of accuracy.  The choice of 
classification method is ultimately left to the discretion of the investigator or clinician 
and is dependent upon the data that is available.  The results achieved using the three 
most common classification methods have never been systematically compared and 
published in the peer review literature.  If a high level of inconsistency in categorization 
exists depending on which of the three classification methods is utilized then study 
results and decisions made for patients would largely depend upon the method used, and 
would vary by classification scheme. 
In this study, we define and characterize MRSA infections reported in Michigan 
as either HA or CA based upon each of the three classification schemes: healthcare risk 
factor, infection type, and susceptibility pattern.  We then compare and contrast the three 







 MRSA surveillance was conducted by the Michigan Department of Community 
Health (MDCH) from October 1, 2004 through December 31, 2005.  Surveillance was 
carried out as a designated medical research project for public health purposes, which 
permits collection of data of public health significance without having to revise the 
reportable disease list to make this reporting mandatory.  This allows for more specific 
data from both HA-MRSA and CA-MRSA infections to be collected to help 
epidemiologically characterize these cases in Michigan.  The data submission for 
individual MRSA cases under this designation is voluntary, although the reporting of 
MRSA outbreaks is mandatory by law in Michigan.  This research project was approved 
by the MDCH Chief Medical Executive and the MDCH Human Subjects Committee, as 
well as the University of Michigan Institutional Review Board.  The request to report 
individual MRSA cases to MDCH was announced statewide via letters, updates to 
reporting guidelines, and presentations to healthcare providers, laboratories, and local 
health departments throughout the state.  Individual cases of MRSA infection were 
voluntarily reported through local health departments to the MDCH Antimicrobial 
Resistance Epidemiologist.  Information was submitted using a two-page MDCH MRSA 
Surveillance Case Report Form and laboratory susceptibility test result sheets. 
 A total of 2,227 unduplicated MRSA cases were reported by private physicians, 
correctional facilities, infection control professionals, hospital laboratories, and local 
health departments throughout Michigan from October 1, 2004 through December 31, 




Michigan residence (n=19) and infection type specified as none (n=54) or colonization 
(n=3).  The dataset used for the analyses contained 2,151 unique MRSA infections 
among Michigan residents. 
Data Management 
 All cases in the dataset were defined as either HA-MRSA or CA-MRSA, three 
separate times based upon the three different classification schemes: healthcare risk 
factor, infection type, and susceptibility pattern. 
Classified by healthcare risk factor 
Cases were labeled as HA-MRSA on the basis of healthcare risk factor if they had 
at least one of the following established risk factors: were hospitalized >48 hours prior to 
the current infection (i.e., patient was not MRSA-infected at time of hospitalization but 
culture and infection were identified > 48 hours after admission), were in an intensive 
care unit (ICU) >48 hours prior to the current infection, were hospitalized in the previous 
year (i.e., admitted and discharged from a hospital at any time during the year prior to the 
current infection), had surgery in the previous year, received dialysis in the previous year, 
had a percutaneous device or indwelling catheter in the previous year, or if they resided 
in a long-term care (LTC), nursing home or rehabilitation facility in the previous year 
[40, 51, 52].  Cases with “no” reported for all seven HA-MRSA risk factors (i.e., had 
none of the established risk factors) were considered CA-MRSA by default. 
Classified by infection type 
Cases were labeled as CA-MRSA on the basis of infection type if a skin or soft 
tissue infection was diagnosed, including abscess, cellulitis, folliculitis, and impetigo, or 




serious infections, including bacteremia, meningitis, osteomyelitis, pneumonia, septic 
arthritis, and surgical site infection were labeled as HA-MRSA.  CA-MRSA can in some 
situations, cause more serious infections like pneumonia or bacteremia, but these 
infections are more typically caused by HA-MRSA and are usually accompanied by the 
HA-MRSA risk factors listed previously [29, 46].  Therefore, if a case had both a skin or 
soft tissue infection and more invasive infection concurrently, it was considered HA-
MRSA to give more weight to the more serious infection type.  Only thirteen cases met 
this criterion with either skin/soft tissue infection and bacteremia (n=8) or skin/soft tissue 
infection and pneumonia (n=5) present simultaneously. 
Classified by susceptibility pattern 
Cases were labeled as CA-MRSA on the basis of susceptibility pattern if their 
isolates were resistant only to β-lactams, including cephalosporins and carbapenems.  
This is the basic resistance pattern that defines MRSA [53].  Cases were labeled as HA-
MRSA if resistance to additional antimicrobial classes beyond β-lactams, including 
cephalosporins and carbapenems, was also reported.  This higher resistance included, but 
was not limited to, aminoglycosides, folate pathway inhibitors, lincosamides, 
fluoroquinolones, and tetracyclines.  Erythromycin, a macrolide, was not used in the 
susceptibility pattern categorization, based on research showing increased CA-MRSA 
resistance to erythromycin [33, 43, 54] and the large overall proportion of erythromycin-
resistance in this Michigan dataset. 
Data Analysis 
The 2,151 MRSA infection cases included in this study were categorized as HA-




schemes described above: healthcare risk factor, infection type, and susceptibility pattern.  
Univariate analyses were conducted for each of the three classifications to provide a 
comparison of demographic and clinical patterns of HA-MRSA versus CA-MRSA 
infections in Michigan.  Frequencies, percentages, and distributions of HA-MRSA versus 
CA-MRSA infections are reported for each of the three classification methods by gender, 
race, age, hospitalized during time of MRSA infection, survival during time of MRSA 
infection, preexisting medical conditions, type of infection, healthcare risk factors, and 
susceptibilities to specific antimicrobial agents.  Chi-square and Fisher’s exact tests 
(when expected cell frequencies were <5) were performed on categorical variables to test 
for significant differences in proportions between HA-MRSA and CA-MRSA defined 
cases.  The t-test was used to make the comparison between HA-MRSA and CA-MRSA 
cases for the continuous age variable.  Results of the MRSA categorizations by the three 
classifications are then compared for each case and the overall concordance/discordance 
of results determined.  Results were considered statistically significant if the p-value was 
<0.05.  All statistical analyses were conducted using SAS® statistical software (SAS 
System for Windows V9.1.3, SAS Institute Inc., Cary, NC). 
 
Results 
 Of the total 2,151 cases analyzed in this investigation, 1,188 (55%) were male and 
the mean age of all cases was 44 years old (s.d.=25 years).  The race/ethnicity distribution 
was as follows: 1,293 (60%) white, 382 (18%) black, 81 (4%) “other” (i.e., 
Hispanic/Latino, American Indian/Alaskan Native, Asian, or Native Hawaiian/Pacific 




during time of MRSA infection, 80 (4%) died during time of MRSA infection, 1,338 
(62%) had at least one preexisting illness reported, while 315 (15%) were reported as 
having no preexisting illnesses and 498 (23%) were reported as unknown. 
Classified by healthcare risk factor 
 Statistically significant results from the categorization of MRSA (HA or CA) by 
healthcare risk factor are presented in Table 2.1.  According to this classification, 37% of 
cases are HA-MRSA and 63% are CA-MRSA.  A greater proportion of males had CA-
MRSA infections than females, while the distribution was almost equal in the HA-MRSA 
group (p=0.005).  The higher proportion of whites was in the HA-MRSA group, but the 
higher proportion of blacks was in the CA-MRSA group (p=0.009).  The mean age for 
HA-MRSA infections was 58 years old (s.d.=23 years), and for CA-MRSA was 35 years 
old (s.d.=21 years) (p<0.0001).  The highest proportions of HA-MRSA infections 
occurred among those 50 years and older, while the highest proportions of CA-MRSA 
infections occurred among those younger than 50 years old (p<0.0001) (Figure 2.1).  
Sixty-two percent of the individuals with HA-MRSA infections were hospitalized, while 
22% with CA-MRSA were hospitalized during time of MRSA infection (p<0.0001).  Of 
the individuals with HA-MRSA, 10% died during time of MRSA infection compared to 
only 1% with CA-MRSA (p<0.0001).  HA-MRSA infected individuals suffered from 
more preexisting illnesses than those with CA-MRSA, including diabetes mellitus, 
chronic renal insufficiency, dialysis, cardiovascular disease, coronary heart failure, 
chronic obstructive pulmonary disease, and overall “any” preexisting illness (for each 
illness, p<0.0001).  Of the five most common infection types of those investigated, 




(p<0.0001), while those with HA-MRSA suffered from bacteremia, pneumonia, and 
surgical site infections (for each infection type, p<0.0001).  The proportion of individuals 
with “wound” infections did not differ significantly between the HA- and CA-MRSA 
groups (p=0.363), most likely due to the vagueness of this term, which is generically used 
to describe infections in both healthcare and community settings.  Of the non-β-lactam 
drugs evaluated, the HA-MRSA infected group was more likely to be resistant to 
ciprofloxacin, clindamycin, gentamicin, levofloxacin, and trimethoprim-
sulfamethoxazole (for each drug, p<0.0001) compared to the CA-MRSA group. 
Classified by infection type 
 Statistically significant results from the categorization of MRSA (HA or CA) by 
infection type are presented in Table 2.2.  According to this classification, 39% of cases 
are HA-MRSA and 61% are CA-MRSA; 393 cases are unknown due to missing infection 
type data.  A greater proportion of males had CA-MRSA infections than females, while 
the distribution was almost equal in the HA-MRSA group (p=0.0003).  The higher 
proportion of whites was in the HA-MRSA group, but the higher proportion of blacks 
was in the CA-MRSA group (p<0.0001).  The mean age for HA-MRSA infections was 
60 years old (s.d.=23 years), and for CA-MRSA was 35 years old (s.d.=20 years) 
(p<0.0001).  The highest proportions of HA-MRSA infections occurred among those 50 
years and older, while the highest proportions of CA-MRSA infections occurred among 
those younger than 50 years old (p<0.0001) (Figure 2.2).  Sixty-six percent of the 
individuals with HA-MRSA infections were hospitalized, while 23% with CA-MRSA 
were hospitalized during time of MRSA infection (p<0.0001).  Of the individuals with 




MRSA (p<0.0001).  HA-MRSA infected individuals suffered from more preexisting 
illnesses than those with CA-MRSA, including diabetes mellitus, chronic renal 
insufficiency, dialysis (p=0.0006), cardiovascular disease, coronary heart failure, chronic 
obstructive pulmonary disease, and overall “any” preexisting illness (for each illness not 
previously specified, p<0.0001).  Those with HA-MRSA infections were more likely to 
have: been hospitalized >48 hours prior to the current infection, in ICU >48 hours prior 
to the current infection, hospitalized in the previous year, had surgery in the previous 
year, received dialysis in the previous year, had a percutaneous device or indwelling 
catheter in the previous year, and/or resided in a LTC, nursing home or rehabilitation 
facility in the previous year compared to those with CA-MRSA (for each risk factor, 
p<0.0001).  Of the non-β-lactam drugs evaluated, the HA-MRSA infected group was 
more likely to be resistant to ciprofloxacin, clindamycin, gentamicin, levofloxacin, and 
trimethoprim-sulfamethoxazole (for each drug, p<0.0001) compared to the CA-MRSA 
group. 
Classified by susceptibility pattern 
 Statistically significant results from the categorization of MRSA (HA or CA) by 
susceptibility pattern are presented in Table 2.3.  According to this classification, 54% of 
cases are HA-MRSA and 46% are CA-MRSA; 63 cases are unknown due to missing 
susceptibility pattern data.  A greater proportion of males had CA-MRSA infections than 
females, while the distribution was more equal in the HA-MRSA group (p=0.007).  The 
higher proportion of whites was in the HA-MRSA group, but the higher proportion of 
blacks was in the CA-MRSA group (p<0.0001).  The mean age for HA-MRSA infections 




(p<0.0001).  The highest proportions of HA-MRSA infections occurred among those 40 
years and older, while the highest proportions of CA-MRSA infections occurred among 
those younger than 40 years old (p<0.0001) (Figure 2.3).  Fifty-one percent of the 
individuals with HA-MRSA infections were hospitalized, while 22% with CA-MRSA 
were hospitalized during time of MRSA infection (p<0.0001).  Of the individuals with 
HA-MRSA, 8% died during time of MRSA infection compared to only 1% with CA-
MRSA (p<0.0001).  HA-MRSA infected individuals suffered from more preexisting 
illnesses than those with CA-MRSA, including diabetes mellitus, chronic renal 
insufficiency, dialysis, cardiovascular disease, coronary heart failure, chronic obstructive 
pulmonary disease, and overall “any” preexisting illness (for each illness, p<0.0001).  
Those with HA-MRSA infections were more likely to have: been hospitalized >48 hours 
prior to the current infection, in ICU >48 hours prior to the current infection, hospitalized 
in the previous year, had surgery in the previous year, received dialysis in the previous 
year, had a percutaneous device or indwelling catheter in the previous year, and/or 
resided in a LTC, nursing home or rehabilitation facility in the previous year compared to 
those with CA-MRSA (for each risk factor, p<0.0001).  Of the five most common 
infection types of those investigated, individuals with CA-MRSA were most likely to 
have skin/soft tissue infections (p<0.0001), while those with HA-MRSA suffered from 
bacteremia, pneumonia, and surgical site infections (for each infection type, p<0.0001).  
The proportion of individuals with “wound” infections did not differ significantly 
between the HA- and CA-MRSA groups (p=0.638), most likely due to the vagueness of 






Results from the concordance/discordance analysis are shown in Table 2.4 and 
reveal that of the 2,151 cases, 427 (20%) cases are consistently defined as HA-MRSA 
infections by all three classifications, while 548 (25%) cases are consistently defined as 
CA-MRSA infections by all three classifications.  Of the total cases, 897 (42%) are not 
consistently defined by the three different classifications.  Of these discordant cases, 292 
are defined as HA-MRSA by two classifications and CA-MRSA by a third classification, 
437 are defined as CA-MRSA by two classifications and HA-MRSA by a third 
classification, and 168 are defined as HA-MRSA by one classification, as CA-MRSA by 
a second classification, and are missing results that could not be calculated for a third 
classification.  There are 279 (13%) cases where concordance/discordance results could 
not be fully determined by all three classifications because of incomplete case data.  Of 
these cases, 68 are defined as HA-MRSA by two classifications and are missing data 
necessary to categorize by the third classification method, 202 are defined as CA-MRSA 
by two classifications with missing data for the third classification, and finally, a small 
number of cases (i.e., 2 cases of HA-MRSA and 7 cases of CA-MRSA) had only 
sufficient data to categorize based on a single classification.  Missing data in Table 2.4 is 
due to unknown infection type in 393 (18%) of the total case population (Table 2.2), and 
unknown susceptibility pattern in 63 (3%) of the total case population (Table 2.3).  Nine 








MRSA infections in this dataset are defined as HA or CA by the classification 
schemes: healthcare risk factor, infection type, and susceptibility pattern (Tables 2.1-2.3).  
The demographic, clinical, and microbiologic variables showed similar distributions 
within the HA and CA categorizations among the three classification methods, and are 
consistent with those seen in previously published literature, according to the differing 
presentations of HA- and CA-MRSA [30-38].  The HA-MRSA group encompasses 
individuals who are at greater risk for becoming infected by this opportunistic pathogen 
because they unwittingly present the opportunity.  These individuals are generally older, 
have chronic underlying illnesses, and require more frequent interactions with healthcare 
facilities, all of which predispose them to more serious and resistant infections.  The CA-
MRSA group includes individuals who, in general, are otherwise healthy.  They are 
usually not predisposed by age or underlying illness to these infections, but by specific 
activities and community interactions that place them at an increased risk for acquisition.  
In this study population, the proportion of males and the proportion of blacks with CA-
MRSA infections were higher compared to their HA-MRSA counterparts.  Studies have 
shown that a higher percentage of men are more likely to engage in “close contact” 
sports, have more cuts and skin abrasions, and live in close congregate settings like 
military barracks or correctional facilities, all previously established risk factors for CA-
MRSA [18, 23, 24].  Studies have also reported a higher prevalence of CA-MRSA 
infections among males in urban settings, men who have sex with men, and drug users [3, 




It would appear that all three classifications are accurate, yield very similar 
results, and could be used interchangeably to define an MRSA infection as HA or CA, 
based on the consistent distributions of descriptive variables within the HA and CA 
categories for each of the three classification methods.  A discrepancy between these 
three methods is first seen when comparing the overall proportions of HA versus CA 
cases within each of the classifications; these distributions are similar for healthcare risk 
factor and infection type, but are notably different for susceptibility pattern.  Additional 
analysis reveals concordance across all three classifications for only 975 (45%) of the 
cases (Table 2.4).  897 (42%) of the cases are consistently defined as HA or CA based on 
two of the classifications, but not the third.  The remaining 279 (13%) cases are missing 
data that prevent comparison of all three classification methods. 
The large number of discordant cases, 897 or 42% of the total MRSA cases 
reported, are of concern with regard to defining MRSA infections as HA or CA.  These 
results indicate that the classification of a case as HA or CA is dependent on the method 
chosen.  Healthcare risk factor is the inconsistent result for 223 of the cases, infection 
type is the inconsistent result for 177 of the cases, and susceptibility pattern is the 
inconsistent result for 329 of the cases.  Each of the three classification methods is 
inconsistent with the other two, for a number of cases, so it is not possible to identify one 
method as the most accurate.  These noted inconsistencies are somewhat inherent, 
because each classification scheme defines an MRSA infection using a different 
characteristic; one considers healthcare interactions of the patient, the second the 
presentation of infection, and the third the genetic makeup of the pathogen.  Each piece 




information together would provide a more complete picture of the MRSA infection; how 
it was acquired, how it presented, and the specific makeup of the pathogen.  This is 
important as MRSA is continually evolving and some studies indicate that the settings for 
HA and CA infections may have begun to overlap.  These results suggest that further 
investigation is needed and analyses should be conducted to search for a more reliable 
combination of variables that can be used to define MRSA infection as either HA or CA.  
This new combination may or may not include the three currently utilized classification 
schemes of healthcare risk factor, infection type, and susceptibility pattern.  In addition, 
other variables should be considered, including age, hospitalization, survival, and 
preexisting illness. 
There are some limitations to this categorization investigation.  Data were 
abstracted from medical chart reviews, not patient interviews, therefore information on 
healthcare risk factors and preexisting illnesses may not be all inclusive.  The data were, 
however, complete for all seven healthcare risk factors with either a “yes” or “no” answer 
submitted.  There are also missing data for some of the demographic, infection type, and 
susceptibility pattern variables.  A more complete and accurate dataset would strengthen 
the results and help to determine the concordance/discordance for the remaining 13% of 
cases, but the proportion of cases missing data was low compared to the data obtained 
from the large number of cases reported.  And from the available data, a large number of 
categorizations were shown to be discordant (42%).  The outcomes for hospitalization 
and survival were not strictly due to MRSA, though these variables do represent 
seriousness of illness and serve as proxies during the same time frame as the MRSA 




HA- and CA-MRSA infections throughout Michigan, because this surveillance was 
voluntary.  The data that were collected do provide the necessary case and variable 
distributions to address the goal of this investigation; to categorize by the three 
classification methods and test for concordance/discordance. 
In conclusion, the data on MRSA infections submitted from throughout Michigan 
for a 15 month period provided reliable information from a variety of sources and 
patients.  The 2,151 cases used in these analyses offered a broad range of MRSA 
infections among individuals with varying demographics and health risk factors.  This 
investigation showed that the relationship between MRSA categorization (HA or CA) 
and a variety of demographic and health-related covariates were similar across 
classification method.  Defining MRSA infections as either HA or CA by healthcare risk 
factor, infection type, or susceptibility pattern yielded similar proportions by the first two 
criteria (37% and 39% HA, respectively), but more HA classification (54%) using the 
third criterion.  Given that the three criteria reflect different aspects of the disease, it is 
not necessarily surprising that they are only modestly concordant.  However, the degree 
of discordance among the three classification methods makes it clear that consistent 
comparisons cannot be made.  Further investigations should consider a gold standard 
molecular test, like pulsed field gel electrophoresis, and other patient descriptive 
variables, in addition to the three classification schemes, to find a more accurate and 
consistent way to define MRSA infections as HA or CA.  A more accurate profile of an 
MRSA infection allows for more appropriate messages for control of transmission and 
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Table 2.1. Michigan MRSA Infections Classified by Healthcare Risk Factor as 






 N=805 (37%) N=1346 (63%)  
 n (%) n (%)  
Gender: Male 413 (51) 775 (58) 0.005 
 Race: White 538 (78) 755 (71) 0.009 
           Black 127 (18) 255 (24)  
           Other 28 (4) 53 (5)  
Age: (range: 0-80+) 794 (=58 s.d.=23) 1327 (=35 s.d.=21) <0.0001 
Hospitalized: Yes 487 (62) 252 (22) <0.0001 
Survival: Died 68 (10) 12 (1) <0.0001 
Preexisting Illness(s):    
          None 42 (5) 273 (30) <0.0001 
          Diabetes Mellitus 259 (34) 103 (11) <0.0001 
          Chronic Renal Insufficiency 112 (15) 18 (2) <0.0001 
          Dialysis 41 (5) 4 (.4) <0.0001 
          Cardiovascular Disease 184 (24) 61 (7) <0.0001 
          Coronary Heart Failure 161 (21) 28 (3) <0.0001 
          COPD 159 (21) 48 (5) <0.0001 
          Any Preexisting Illness 714 (94) 624 (70) <0.0001 
Infection Type:    
          Bacteremia 76 (10) 16 (2) <0.0001 
          Pneumonia 152 (21) 25 (2) <0.0001 
          Skin / Soft Tissue 233 (31) 841 (83) <0.0001 
          Surgical Site 52 (7) 10 (1) <0.0001 
Drug Resistance:    
          Ciprofloxacin 187 (75) 173 (37) <0.0001 
          Clindamycin 356 (66) 200 (22) <0.0001 
          Gentamicin 54 (8) 21 (2) <0.0001 
          Levofloxacin 537 (77) 345 (33) <0.0001 
          Trimeth.-Sulfamethoxazole 17 (2) 5 (.41) <0.0001 




















Figure 2.1. Age Group Distribution of Michigan MRSA Infections Classified by 
































Table 2.2. Michigan MRSA Infections Classified by Infection Type as Healthcare-






 N=684 (39%) N=1074 (61%)  
 n (%) n (%)  
Gender: Male 351 (51) 646 (60) 0.0003 
Race: White 463 (80) 604 (67) <0.0001 
          Black 91 (16) 251 (28)  
          Other 24 (4) 47 (5)  
Age   0-80+ 678 (=60 s.d.=23) 1058 (=35 s.d.=20) <0.0001 
Hospitalized: Yes 441 (66) 238 (23) <0.0001 
Survival: Died 68 (11) 5 (1) <0.0001 
Preexisting Illness(s):    
          None 34 (5) 261 (29) <0.0001 
          Diabetes Mellitus 221 (34) 108 (12) <0.0001 
          Chronic Renal Insufficiency 95 (15) 24 (3) <0.0001 
          Dialysis 28 (4) 13 (1) 0.0006 
          Cardiovascular Disease 159 (24) 70 (8) <0.0001 
          Coronary Heart Failure 142 (22) 28 (3) <0.0001 
          COPD 156 (24) 34 (4) <0.0001 
          Any Preexisting Illness 608 (95) 620 (71) <0.0001 
Healthcare Risk Factors:    
          Hospitalized >48 hours 112 (16) 31 (3) <0.0001 
          In ICU >48 hours 60 (9) 8 (1) <0.0001 
          Hospitalized in Prior Year 345 (50) 162 (15) <0.0001 
          Surgery in Prior Year 195 (29) 101 (9) <0.0001 
          Dialysis in Prior Year 37 (5) 16 (1) <0.0001 
          Indwell Device in Prior Yr 198 (29) 64 (6) <0.0001 
          LTC/Rehab in Prior Year 204 (30) 46 (4) <0.0001 
Drug Resistance:    
          Ciprofloxacin 166 (83) 121 (33) <0.0001 
          Clindamycin 323 (71) 130 (18) <0.0001 
          Gentamicin 49 (8) 13 (1) <0.0001 
          Levofloxacin 488 (82) 260 (30) <0.0001 
          Trimeth.-Sulfamethoxazole 17 (3) 4 (.42) <0.0001 


















Figure 2.2. Age Group Distribution of Michigan MRSA Infections Classified by 
































Table 2.3. Michigan MRSA Infections Classified by Susceptibility Pattern as Healthcare-






 N=1119 (54%) N=969 (46%)  
 n (%) n (%)  
Gender: Male 587 (52) 565 (58) 0.007 
Race: White 714 (78) 531 (67) <0.0001 
          Black 164 (18) 214 (27)  
          Other 32 (4) 46 (6)  
Age   0-80+ 1110 (=54 s.d.=24) 950 (=32 s.d.=19) <0.0001 
Hospitalized: Yes 529 (51) 181 (22) <0.0001 
Survival: Died 73 (8) 5 (1) <0.0001 
Preexisting Illness(s):    
          None 101 (11) 207 (29) <0.0001 
          Diabetes Mellitus 277 (30) 65 (9) <0.0001 
          Chronic Renal Insufficiency 113 (12) 10 (1) <0.0001 
          Dialysis 37 (4) 5 (1) <0.0001 
          Cardiovascular Disease 197 (21) 36 (5) <0.0001 
          Coronary Heart Failure 164 (18) 17 (2) <0.0001 
          COPD 172 (19) 25 (4) <0.0001 
          Any Preexisting Illness 812 (89) 481 (70) <0.0001 
Healthcare Risk Factors:    
          Hospitalized >48 hours 120 (11) 26 (3) <0.0001 
          In ICU >48 hours 56 (5) 11 (1) <0.0001 
          Hospitalized in Prior Year 415 (37) 115 (12) <0.0001 
          Surgery in Prior Year 243 (22) 69 (7) <0.0001 
          Dialysis in Prior Year 44 (4) 7 (1) <0.0001 
          Indwell Device in Prior Yr 216 (19) 45 (5) <0.0001 
          LTC/Rehab in Prior Year 226 (20) 30 (3) <0.0001 
Infection Type:    
          Bacteremia 76 (8) 14 (2) <0.0001 
          Pneumonia 151 (16) 19 (2) <0.0001 
          Skin / Soft Tissue 389 (42) 657 (85) <0.0001 
          Surgical Site 51 (5) 9 (1) <0.0001 



















Figure 2.3. Age Group Distribution of Michigan MRSA Infections Classified by 
































Table 2.4. Comparison of MRSA Infections Categorized by the Three Classifications 
(Healthcare Risk Factor, Infection Type, Susceptibility Pattern) as Either 










# of Cases Matching 
Row Combination 
Results  [n, %] 
Concordant 1 1 1 427  (20) 
 0 0 0 548  (25) 
 Total: 975  (45%) 
Discordant 1 1 0 59  (3) 
 1 0 1 119  (5) 
 0 1 1 114  (5) 
 0 0 1 270  (13) 
 0 1 0 58  (3) 
 1 0 0 109  (5) 
 1 0 . 5  (.2) 
 1 . 0 16  (.7) 
 0 1 . 4  (.1) 
 0 . 1 143  (7) 
 Total: 897  (42%) 
Unable to  1 1 . 22  (1) 
Determine 1 . 1 46  (2) 
 1 . . 2  (.5) 
 0 0 . 23  (1) 
 0 . 0 179  (8) 
 0 . . 7  (.5) 
 Total: 279  (13%) 














1. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A and Lucet JC. Duration of 
colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and 
risk factors for prolonged carriage. Clin Infect Dis 2001;32:1393-8 
 
2. Price MF, Carlini M, Houston S and Gentry LO. Prevalence of nasal colonization with 
methicillin-resistant Staphylococcus aureus in selected patient populations. Infect Control 
Hosp Epidemiol 2000;21:603-5 
 
3. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus 
nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9 
 
4. Jevons MP, Coe AW and Parker MT. Methicillin resistance in staphylococci. Lancet 
1963;1:904-7 
 
5. Haley RW, Hightower AW, Khabbaz RF, et al. The emergence of methicillin-resistant 
Staphylococcus aureus infections in United States hospitals. Possible role of the house 
staff-patient transfer circuit. Ann Intern Med 1982;97:297-308 
 
6. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus 
in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6 
 
7. Wenzel RP. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern 
Med 1982;97:440-2 
 
8. Donowitz LG, Wenzel RP and Hoyt JW. High risk of hospital-acquired infection in the 
ICU patient. Crit Care Med 1982;10:355-7 
 
9. National Nosocomial Infections Surveillance (NNIS) System report, data summary 
from October 1986-April 1998, issued June 1998. Am J Infect Control 1998;26:522-33 
 
10. National Nosocomial Infections Surveillance (NNIS) System Report, data summary 
from January 1992 through June 2004, issued October 2004. Am J Infect Control 
2004;32:470-85 
 
11. Crane LR, Levine DP, Zervos MJ and Cummings G. Bacteremia in narcotic addicts at 
the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric 
therapy. Rev Infect Dis 1986;8:364-73 
 
12. Levine DP, Cushing RD, Jui J and Brown WJ. Community-acquired methicillin-






13. Saravolatz LD, Markowitz N, Arking L, Pohlod D and Fisher E. Methicillin-resistant 
Staphylococcus aureus. Epidemiologic observations during a community-acquired 
outbreak. Ann Intern Med 1982;96:11-6 
 
14. Saravolatz LD, Pohlod DJ and Arking LM. Community-acquired methicillin-resistant 
Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern 
Med 1982;97:325-9 
 
15. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state 
prison--Mississippi, 2000. MMWR Morb Mortal Wkly Rep 2001;50:919-22 
 
16. Methicillin-resistant Staphylococcus aureus infections in correctional facilities---
Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 
2003;52:992-6 
 
17. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin 
infections--Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 
2003;52:88 
 
18. Methicillin-resistant staphylococcus aureus infections among competitive sports 
participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. 
MMWR Morb Mortal Wkly Rep 2003;52:793-5 
 
19. Feder HM, Jr. Methicillin-resistant Staphylococcus aureus infections in 2 pediatric 
outpatients. Arch Fam Med 2000;9:560-2 
 
20. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-
resistant Staphylococcus aureus in children with no identified predisposing risk. Jama 
1998;279:593-8 
 
21. Shahin R, Johnson IL, Jamieson F, McGeer A, Tolkin J and Ford-Jones EL. 
Methicillin-resistant Staphylococcus aureus carriage in a child care center following a 
case of disease. Toronto Child Care Center Study Group. Arch Pediatr Adolesc Med 
1999;153:864-8 
 
22. Zinderman CE, Conner B, Malakooti MA, LaMar JE, Armstrong A and Bohnker BK. 
Community-acquired methicillin-resistant Staphylococcus aureus among military 
recruits. Emerg Infect Dis 2004;10:941-4 
 
23. Lindenmayer JM, Schoenfeld S, O'Grady R and Carney JK. Methicillin-resistant 
Staphylococcus aureus in a high school wrestling team and the surrounding community. 
Arch Intern Med 1998;158:895-9 
 
24. Aiello AE, Lowy FD, Wright LN and Larson EL. Meticillin-resistant Staphylococcus 
aureus among US prisoners and military personnel: review and recommendations for 




25. Cosgrove SE. The relationship between antimicrobial resistance and patient 
outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 
2006;42 Suppl 2:S82-9 
 
26. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of 
care. Crit Care Med 2001;29:N114-20 
 
27. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health 
care-associated methicillin-resistant Staphylococcus aureus infection. Jama 
2003;290:2976-84 
 
28. Fey PD, Said-Salim B, Rupp ME, et al. Comparative molecular analysis of 
community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob 
Agents Chemother 2003;47:196-203 
 
29. Diederen BM, Kluytmans JA. The emergence of infections with community-
associated methicillin resistant Staphylococcus aureus. J Infect 2006;52:157-68 
 
30. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus 
aureus: a review. Pharmacotherapy 2005;25:74-85 
 
31. Palavecino E. Community-acquired methicillin-resistant Staphylococcus aureus 
infections. Clin Lab Med 2004;24:403-18 
 
32. Marcinak JF, Frank AL. Treatment of community-acquired methicillin-resistant 
Staphylococcus aureus in children. Curr Opin Infect Dis 2003;16:265-9 
 
33. Johnson LB, Saeed S, Pawlak J, Manzor O and Saravolatz LD. Clinical and 
laboratory features of community-associated methicillin-resistant Staphylococcus aureus: 
is it really new? Infect Control Hosp Epidemiol 2006;27:133-8 
 
34. Herman RA, Kee VR, Moores KG and Ross MB. Etiology and treatment of 
community-associated methicillin-resistant Staphylococcus aureus. Am J Health Syst 
Pharm 2008;65:219-25 
 
35. Eguia JM, Chambers HF. Community-acquired Methicillin-resistant Staphylococcus 
aureus: Epidemiology and Potential Virulence Factors. Curr Infect Dis Rep 2003;5:459-
466 
 
36. Beam JW, Buckley B. Community-Acquired Methicillin-Resistant Staphylococcus 
aureus: Prevalence and Risk Factors. J Athl Train 2006;41:337-40 
 
37. Boyce JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term 
care facilities: microbiology, epidemiology, and preventive measures. Infect Control 




38. Diep BA, Sensabaugh GF, Somboona NS, Carleton HA and Perdreau-Remington F. 
Widespread skin and soft-tissue infections due to two methicillin-resistant 
Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J 
Clin Microbiol 2004;42:2080-4 
 
39. Fleming SW, Brown LH and Tice SE. Community-acquired methicillin-resistant 
Staphylococcus aureus skin infections: report of a local outbreak and implications for 
emergency department care. J Am Acad Nurse Pract 2006;18:297-300 
 
40. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus 
aureus disease in three communities. N Engl J Med 2005;352:1436-44 
 
41. Hota B, Ellenbogen C, Hayden MK, Aroutcheva A, Rice TW and Weinstein RA. 
Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue 
infections at a public hospital: do public housing and incarceration amplify transmission? 
Arch Intern Med 2007;167:1026-33 
 
42. Johnston CP, Cooper L, Ruby W, Carroll KC, Cosgrove SE and Perl TM. 
Epidemiology of community-acquired methicillin-resistant Staphylococcus aureus skin 
infections among healthcare workers in an outpatient clinic. Infect Control Hosp 
Epidemiol 2006;27:1133-6 
 
43. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus 
infections among patients in the emergency department. N Engl J Med 2006;355:666-74 
 
44. Buck JM, Como-Sabetti K, Harriman KH, et al. Community-associated methicillin-
resistant Staphylococcus aureus, Minnesota, 2000-2003. Emerg Infect Dis 2005;11:1532-
8 
 
45. Faria NA, Oliveira DC, Westh H, et al. Epidemiology of emerging methicillin-
resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country 
with low prevalence of MRSA infection. J Clin Microbiol 2005;43:1836-42 
 
46. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant 
Staphylococcus aureus infections in the United States. Jama 2007;298:1763-71 
 
47. Morin CA, Hadler JL. Population-based incidence and characteristics of community-
onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut 
areas, 1998. J Infect Dis 2001;184:1029-34 
 
48. Said-Salim B, Mathema B and Kreiswirth BN. Community-acquired methicillin-






49. Walker ES, Vasquez JE, Dula R, Bullock H and Sarubbi FA. Mupirocin-resistant, 
methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect 
Control Hosp Epidemiol 2003;24:342-6 
 
50. Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-
acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin 
Infect Dis 2001;33:990-6 
 
51. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J 
Med 1989;320:1188-96 
 
52. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32 
 
53. Clincal and Laboratory Standards Institute.  Performance Standards for Antimicrobial 
Susceptibility Testing. Sixteenth informational supplement. M100-S18. Wayne PA, 2008.  
 
54. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK and Tenover 
FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus 
isolates from the United States: establishing a national database. J Clin Microbiol 
2003;41:5113-20 
 
55. Bratu S, Landman D, Gupta J, Trehan M, Panwar M and Quale J. A population-based 
study examining the emergence of community-associated methicillin-resistant 
Staphylococcus aureus USA300 in New York City. Ann Clin Microbiol Antimicrob 
2006;5:29 
 
56. Huang H, Cohen SH, King JH, Monchaud C, Nguyen H and Flynn NM. Injecting 
drug use and community-associated methicillin-resistant Staphylococcus aureus 
infection. Diagn Microbiol Infect Dis 2008;60:347-50 
 
57. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic 
characteristics cannot distinguish community-associated methicillin-resistant 
Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a 
prospective investigation. Clin Infect Dis 2007;44:471-82 
 
58. Shastry L, Rahimian J and Lascher S. Community-associated methicillin-resistant 
Staphylococcus aureus skin and soft tissue infections in men who have sex with men in 
New York City. Arch Intern Med 2007;167:854-7 
 
59. Zafar U, Johnson LB, Hanna M, et al. Prevalence of nasal colonization among 
patients with community-associated methicillin-resistant Staphylococcus aureus infection 








A Proposed New Multivariable Model to Define Methicillin-Resistant 




Background: Methicillin-resistant Staphylococcus aureus (MRSA) infections are 
often defined as healthcare- (HA) or community-associated (CA) using one of three 
classification schemes: healthcare risk factor, infection type, or susceptibility pattern.  All 
three of these methods have been shown to produce discordant results when compared.  
A fourth method utilized for the classification of MRSA as HA or CA is laboratory 
molecular typing.  This investigation uses pulsed-field gel electrophoresis (PFGE) test 
result as a gold standard against which an entirely new classification method will be 
compared.  Development of the new classification method considered the three 
commonly used classification variables along with other important contributing variables 
simultaneously, in order to improve categorization of an MRSA infection as HA or CA. 
Methods: A dataset of 2,151 MRSA infections in Michigan were voluntarily 
reported to the Michigan Department of Community Health (MDCH) between October 1, 
2004 and December 31, 2005.  Patient demographic, risk factor, and infection 
information was recorded on the MDCH MRSA Surveillance Case Report Form and 




of 244 MRSA infections with available PFGE results were analyzed to find the best set of 
predictors of the PFGE result.  Logistic regression was used and results were presented as 
sensitivity/specificity, predictive value, and receiver operating characteristic (ROC) 
curves. 
Results: The identified logistic regression model was better able to predict the 
PFGE classification as HA or CA (Max-rescaled R2 = 61%) then any of the currently 
used classification methods: healthcare risk factor, infection type, or susceptibility pattern 
(Max-rescaled R2 = 21%, 34%, 46%, respectively).  The variables in the best logistic 
model were infection type, susceptibility pattern, age, and hospitalized during the time of 
MRSA infection. 
Conclusion: This investigation has established an improved method to categorize 
MRSA infections as HA or CA using a combination of predictor variables.  The 





 Methicillin-resistant Staphylococcus aureus (MRSA) has been a common cause 
of human infections in the Unites States in both the healthcare and community settings 
since the 1980s [1-6].  Epidemiologically, MRSA infections present differently in these 
two settings in persons of varying age groups and with different health risk factors [7-9].  
Clinically, these organisms cause a broad range of infection types that require varying 
treatment modalities [10-13].  The numbers of MRSA infections in both the healthcare 
and community settings continue to rise and can pose a significant morbidity and 
mortality risk to those who are infected.  Therefore, understanding and being able to 
differentiate between healthcare and community MRSA strains is important for the 
improvement of targeted public health and infection control prevention and intervention 
strategies. 
Laboratory molecular strain typing methods have proved invaluable in tracking 
and characterizing the organisms that cause MRSA infections.  Of the variety of strain 
typing methods available, pulsed-field gel electrophoresis (PFGE) has proven to be more 
discriminating among MRSA strain types than other typing methods (e.g. multilocus 
sequence typing, etc.).  Specifically, PFGE has been more successful at distinguishing 
between clusters of strains with different virulence characteristics and different 
epidemiological profiles [14].  Consequently, the results from this method of strain typing 
are an important component in identifying an MRSA infection as healthcare-associated 
(HA) or community-associated (CA). 
The U.S. Centers for Disease Control and Prevention (CDC) used PFGE to 




national database of PFGE patterns in 2003.  Eight lineages were identified from these 
isolates and were designated as pulsed-field types (PFTs) USA100 through USA800 [14].  
When epidemiologic data were linked to the isolates, it was determined that USA100 and 
USA200 were the two most common healthcare-associated PFTs.  Less common 
healthcare-associated PFTs include 500, 600, and 800.  These isolates had in common 
that they occurred in healthcare facilities, were multi-resistant to commonly used 
therapeutic agents, and carried the staphylococcal chromosomal cassette mec (SCCmec) 
type II.  In contrast, USA300 and USA400 were the two community-associated PFTs.  
These isolates were different in that they occurred in community settings, were 
predominantly found in skin infections, were resistant only to β-lactam drugs and often to 
erythromycin, carried SCCmec type IV, and often harbored the Panton-Valentine 
leukocidin (PVL) virulence determinant.  USA700 isolates were associated with both 
healthcare and community settings [14]. 
The PFGE method of MRSA strain typing has been adopted nationally based on 
validation studies and its accuracy, which provides researchers with a consistent and 
standardized tool to differentiate between HA-MRSA and CA-MRSA isolates.  There are 
still problems, however, that remain with PFGE typing.  It requires three days to perform, 
is expensive, calls for specialized laboratory training, is not readily available in most 
clinical laboratories, and lacks any patient details.  Therefore, the challenge remains to 
find a faster, less expensive, and more readily available way to identify MRSA infections 
as healthcare- versus community-associated, while matching the discriminatory ability of 
PFGE profiles and considering patient characteristics.  A more efficient and less 




for more prompt and effective transmission prevention and timely risk intervention 
efforts. 
This investigation uses a subset of the Michigan MRSA surveillance dataset, 
which was previously analyzed to address the potential for misclassifying MRSA 
infections as healthcare- or community-associated when using only a single classification 
scheme; healthcare risk factor, infection type, or susceptibility pattern.  This subset 
comprises 244 MRSA cases with both classification data and PFGE typing results 
available.  Logistic regression was used with PFGE result as the outcome variable and 
potential predictors including gender, race, age, hospitalized, survival, preexisting 
medical conditions, healthcare risk factor, infection type, and susceptibility pattern.  
Sensitivity, specificity, and predictive values were calculated, and receiver operating 
characteristic (ROC) curves were plotted.  Discriminant analysis was used to confirm 
results.  The goal of this research was to improve prediction of MRSA infections as 
healthcare- or community-associated, as determined by PFGE test result, by using 
multivariable statistical methods, in contrast to previous methods that have based 




 The data used for this investigation is a subset of cases collected by the Michigan 
Department of Community Health (MDCH) MRSA Surveillance project.  MRSA 
surveillance was conducted by MDCH from October 1, 2004 through December 31, 




health purposes, which permits collection of data of public health significance without 
having to revise the reportable disease list to make this reporting mandatory.  This allows 
for more specific data from both HA-MRSA and CA-MRSA infections to be collected to 
help epidemiologically characterize these cases in Michigan.  The data submission for 
individual MRSA cases under this designation is voluntary, although the reporting of 
MRSA outbreaks is mandatory by law in Michigan.  This research project was approved 
by the MDCH Chief Medical Executive and the MDCH Human Subjects Committee, as 
well as the University of Michigan Institutional Review Board.  The request to report 
individual MRSA cases to MDCH was announced statewide via letters, updates to 
reporting guidelines, and presentations to healthcare providers, laboratories, and local 
health departments throughout the state.  Individual cases of MRSA infection were 
voluntarily reported through local health departments to the MDCH Antimicrobial 
Resistance Epidemiologist.  Information was submitted using a two-page MDCH MRSA 
Surveillance Case Report Form and laboratory susceptibility test result sheets. 
From the 2,151 total cases available, molecular typing using PFGE was conducted 
on 244 of these [14, 15].  A subset of the isolates was tested due to the cost and time 
associated with PFGE testing.  The tested isolates were randomly selected from a 
compiled list of cases that had both sufficient epidemiologic data provided on the 
submitted case report form and an isolate submitted for PFGE testing.  These 244 MRSA 
cases were used in the current analyses. 
Data Management 
PFT results from the PFGE molecular typing of the 244 MRSA infection isolates 




Cases identified as USA100, USA200, USA600, or USA800, were defined as HA-
MRSA.  Cases identified as USA300 or USA400 were defined as CA-MRSA.  PFTs 
USA500 and USA700 were not represented in the 244 PFGE results. 
The 244 cases were additionally categorized as HA-MRSA or CA-MRSA by the 
three commonly used classification schemes: healthcare risk factor, infection type, and 
susceptibility pattern.  Cases were labeled as HA-MRSA on the basis of healthcare risk 
factor if they had at least one of the following established risk factors: were hospitalized 
>48 hours prior to the current infection (i.e., patient was not MRSA-infected at time of 
hospitalization but culture and infection were identified > 48 hours after admission), were 
in an intensive care unit (ICU) >48 hours prior to the current infection, were hospitalized 
in the previous year (i.e., admitted and discharged from a hospital at any time during the 
year prior to the current infection), had surgery in the previous year, received dialysis in 
the previous year, had a percutaneous device or indwelling catheter in the previous year, 
or if they resided in a long-term care (LTC), nursing home or rehabilitation facility in the 
previous year [16-18].  Cases with “no” reported for all seven HA-MRSA risk factors 
(i.e., had none of the established risk factors) were considered CA-MRSA by default.   
Cases were labeled as CA-MRSA on the basis of infection type if a skin or soft 
tissue infection was diagnosed, including abscess, cellulitis, folliculitis, and impetigo, or 
if a wound infection had “skin” identified as the culture site.  Cases with other and more 
serious infections, including bacteremia, meningitis, osteomyelitis, pneumonia, septic 
arthritis, and surgical site infection were labeled as HA-MRSA.  CA-MRSA can, in some 
situations, cause more serious infections like pneumonia or bacteremia, but these 




HA-MRSA risk factors previously listed [8, 19].  Therefore, if a case had both a skin or 
soft tissue infection and more invasive infection concurrently, it was considered HA-
MRSA to give more weight to the more serious infection type.  Only thirteen cases met 
this criterion with either skin/soft tissue infection and bacteremia (n=8) or skin/soft tissue 
infection and pneumonia (n=5) present simultaneously. 
Cases were labeled as CA-MRSA on the basis of susceptibility pattern if their 
isolates were resistant only to β-lactams, including cephalosporins and carbapenems.  
This is the basic resistance pattern that defines MRSA [20].  Cases were labeled as HA-
MRSA if resistance to additional antimicrobial classes beyond β-lactams, including 
cephalosporins and carbapenems, was also reported.  This higher resistance included, but 
was not limited to, aminoglycosides, folate pathway inhibitors, lincosamides, 
fluoroquinolones, and tetracyclines.  Erythromycin, a macrolide, was not used in the 
susceptibility pattern categorization, based on research showing increased CA-MRSA 
resistance to erythromycin [11, 14, 21] and the large overall proportion of erythromycin-
resistance in this Michigan dataset. 
The three defined categorization schemes: healthcare risk factor, infection type, 
and susceptibility pattern, are treated as three separate dichotomous classification 
variables (HA=1/CA=0) in all of the analyses described for this investigation.  The other 
predictor variables considered for this investigation were gender, race, age, hospitalized 
during time of MRSA infection (yes/no), survival during time of MRSA infection 
(died/survived), and any preexisting medical conditions (yes if reported any – diabetes 
mellitus, chronic renal insufficiency, dialysis, cardiovascular disease, coronary heart 





 Univariate analyses were conducted to compare the demographic and clinical 
patterns of HA-MRSA versus CA-MRSA infections when classified by PFGE result.  
Frequencies, percentages, and distributions of HA-MRSA and CA-MRSA infections are 
reported by gender, race, age, hospitalized during time of MRSA infection, survival 
during time of MRSA infection, preexisting medical conditions, healthcare risk factors, 
infection type, and susceptibilities to specific antimicrobial agents.  Chi-square and 
Fisher’s exact tests (when expected cell frequencies were <5) were performed on 
categorical variables to test for significant differences in proportions between HA-MRSA 
and CA-MRSA cases.  The t-test was used to make the comparison between HA-MRSA 
and CA-MRSA cases for the continuous age variable. 
 Single-variable logistic regression models with PFGE HA vs. CA categorization 
as the outcome were used to test the significance of the HA/CA categorizations of each of 
the three classification variables: healthcare risk factor, infection type, and susceptibility 
pattern, as well as the demographic and other clinical variables: gender, race, age, 
hospitalized during time of MRSA infection (yes/no), survival during time of MRSA 
infection (died/survived), and any preexisting medical conditions (yes/no).  For the three 
dichotomous classification variables, sensitivity, specificity, predictive values and 
McNemar’s test statistics with exact p-values were calculated. 
 Multivariable logistic regression analyses were conducted, testing demographic 
and clinical variables along with the three dichotomous (HA=1/CA=0) classification 
variables using the method of best subset selection.  Combinations of these variables 




 For the best model, the results were used to plot an ROC curve.  An optimal 
cutpoint from the ROC curve was identified, based on maximizing the sensitivity and 
specificity and minimizing the discordance between the PFGE result and predicted result.  
This point then served as the cutpoint for the new predicted categorization of MRSA as 
HA or CA.  Predicted probabilities of HA were computed for each of the 244 cases 
[Predicted Probability = exp(Xβ) / 1+exp(Xβ)].  If the predicted probability for a case 
was equal to or greater than the cutpoint value, it was classified as HA-MRSA, and if it 
was less than the cutpoint, it was classified as CA-MRSA. 
Discriminant analysis was also conducted using the same predictive variables as 
those used for the logistic regression analyses, to verify the best model and classification 
results.  Comparisons were made to show similarities between results from the logistic 
regression analyses and the discriminant analysis.  All results were considered 
statistically significant if the p-value was <0.05.  All statistical analyses were conducted 




 The study dataset consisted of 244 cases of which 130 (53%) were male.  The 
race/ethnicity distribution was as follows: 151 (62%) white, 39 (16%) black, 10 (4%) 
“other” (which included Hispanic/Latino, American Indian/Alaskan Native, Asian, and 
Native Hawaiian/Pacific Islander), and 44 (18%) unknown.  The mean age was 52 years 
old (s.d.=25 years).  In this population, 176 (72%) were hospitalized during time of 




one preexisting illness reported, while 21 (9%) were reported as having no preexisting 
illnesses and 18 (7%) were reported as unknown for preexisting illness.  These 
distributions for gender, race, and age are similar to those of the total dataset of 2,151 
MRSA cases.  The proportions that were hospitalized (p<0.0001), died (p=0.005), and 
had at least one preexisting illness (p<0.0001) were significantly higher for the subset 
compared to the total dataset (n=2,151 – comparative data not shown). 
There were 159 (65%) cases defined as HA-MRSA and 85 (35%) defined as CA-
MRSA when the 244 MRSA cases in the study dataset were categorized by PFGE result 
(Table 3.1).  There were slightly more males with MRSA infections compared to females, 
but the distributions between the HA- and CA-MRSA categories were not significantly 
different (p=0.6445) for gender.  The higher proportion of whites was in the HA-MRSA 
group, but the higher proportion of blacks was in the CA-MRSA group (p=0.0083).  The 
mean age for HA-MRSA infections was 60 years old (s.d.=22 years), and for CA-MRSA 
was 36 years old (s.d.=21 years) (p<0.0001).  The  highest proportions of HA-MRSA 
infections occurred among those 50 years and older, while the highest proportions of CA-
MRSA infections occurred among those younger than 50 years old (p<0.0001) (Figure 
3.1).  Eighty-eight percent of the individuals with HA-MRSA infections were 
hospitalized during time of MRSA infection, while 49% with CA-MRSA were 
hospitalized (p<0.0001).  Of the individuals with HA-MRSA, 12% died during time of 
MRSA infection compared to 4% with CA-MRSA (p<0.0506).  HA-MRSA infected 
individuals suffered from more preexisting illnesses than those with CA-MRSA, 
including diabetes mellitus (p=0.0012), chronic renal insufficiency (p=0.0175), 




pulmonary disease (p=0.0002), and overall “any” preexisting illnesses (p=0.0054).  
Those with HA-MRSA infections were more likely to have: been hospitalized >48 hours 
prior to the current infection (p<0.0001), in ICU >48 hours prior to the current infection 
(p=0.0057), hospitalized in the previous year (p=0.0002), had surgery in the previous 
year (p=0.0292), had a percutaneous device or indwelling catheter in the previous year 
(p<0.0001), and/or resided in a LTC, nursing home or rehabilitation facility in the 
previous year (p=0.0032) compared to those with CA-MRSA.  Among the five most 
common of the infection types investigated, individuals with CA-MRSA were most likely 
to have skin/soft tissue infections (p<0.0001), while those with HA-MRSA had 
bacteremia (p=0.0010) and pneumonia (p=0.0003).  The proportion of individuals with 
surgical site infections and/or “wound” infections did not differ significantly between the 
HA- and CA-MRSA groups (p=0.2462 and p=0.4677, respectively).  Of the non-β-lactam 
drugs evaluated, the HA-MRSA infected group was more likely to be resistant to 
ciprofloxacin (p=0.0003), clindamycin (p<0.0001), and levofloxacin (p<0.0001) 
compared to the CA-MRSA group. 
 Results for the two-by-two comparisons between the HA-MRSA and CA-MRSA 
categorization based on PFGE and the categorization based on the three different 
classification schemes: healthcare risk factor, infection type, and susceptibility pattern are 
presented in Table 3.2.  Sensitivities, specificities, predictive values (PV), and exact p-
value results from McNemar’s test for agreement for each of the three comparisons are 
shown.  Because each of the classifications being compared in the two-by-two tables has 
the same two infection categories, HA-MRSA and CA-MRSA, the sensitivity for 




infection.  This inverse relationship exists for all of the calculations.  HA sensitivity/CA 
specificity (94%) and CA PV-positive/HA PV-negative (85%) are highest for the 
susceptibility pattern classification when all three methods are compared to PFGE result, 
while CA sensitivity/HA specificity (69%) and HA PV-positive/CA PV-negative (84%) 
are highest for the infection type classification.  McNemar’s tests reveal that the direction 
of this classification based on the infection type and healthcare risk factor will be 
balanced (in the same direction), while classification based on susceptibility pattern will 
misclassify in an unbalanced way (p=0.0034). 
 The goal of the logistic regression analyses was to use the available variables to 
identify a best model with a good fit and a high predictive power.  This was 
accomplished through model building with PFGE result as the outcome, using the log-
likelihood statistic and Max-rescaled R2 statistic to assess model fit (Table 3.3).  Each of 
the classification variables was significant when tested alone in the model (Models 1-3, 
for each variable p<0.0001), but susceptibility pattern (-2 Log L = 212.61 and Max-
rescaled R2 = 0.460) was better in the model than infection type (-2 Log L = 224.39 and 
Max-rescaled R2 = 0.343), which was better then healthcare risk factor (-2 Log L = 
275.90 and Max-rescaled R2 = 0.206).  Infection type and susceptibility pattern were the 
best combination, when the three classification variables were tested in pairs (Models 4-
6).  The healthcare risk factor classification variable, added to the model with 
classification variables infection type and susceptibility pattern, only slightly improved 
the fit and predictive power and was not significant in the model; therefore it was 
eliminated (Model 7).  Infection type and susceptibility pattern classification variables 




this model.  These additional variables were significant individually with PFGE result as 
the outcome, as well as individually with each of the two base variables, and included 
age, hospitalized, survival, and preexisting illnesses (individual testing data not shown).  
Each of these variables tested separately in the base model (with infection type and 
susceptibility pattern) did increase the fit and predictive power of the model.  Age and 
hospitalized were most effective at increasing the fit and predictive power of the model, 
while survival was not significant in the model (Models 8-11).  All four of the additional 
variables were then tested together in the base model with infection type and 
susceptibility pattern to identify the maximum possible fit and predictive power levels 
(Model 12).  The preexisting illnesses variable was removed with very little change to the 
fit and predictive power levels, and it did not test significant in the model (Model 13).  
The survival variable was removed last, with only slight decreases in the fit and 
predictive power, and it did not test significant in the model (Model 14).  The identified 
final best model included the classification variables infection type and susceptibility 
pattern, as well as age and hospitalized, and is identical to the model identified using best 
subset selection.  Figure 3.2 illustrates the distribution of logit probabilities for the HA-
MRSA and CA-MRSA groups as defined by PFGE result from the final best model.  The 
HA cases are more tightly clustered compared to the CA cases, which are more dispersed 
and have a number of cases overlapping the HA logit probabilities.   
 The ROC curve based on the final best logistic regression model is plotted in 
Figure 3.3.  This plot is not symmetrical showing that the sensitivity for HA is higher 
than the sensitivity for CA.  The optimum cutpoint corresponded to a predicted 




80.3%.  To predict whether a case of MRSA infection is healthcare-associated or 
community-associated, from the logistic regression and ROC curve analyses, the 
following equation was used: 
Logit (p) = -4.095 + (1.722*Infection Type) + (2.236*Susceptibility Pattern) +    
               (0.021*Age) + (1.379*Hospitalized) 
 
Age is a continuous variable, Hospitalized is yes/1 or no/0, Infection Type and 
Susceptibility Pattern are HA/1 or CA/0 based on previously explained definitions. 
 
If Predicted Probability >= 0.614 then Predict = HA-MRSA 
 




1 Logit (p)= -4.095+(1.722*1)+(2.236*1) 
             +(0.021*62)+(1.379*1)=2.54 
Predicted Prob =   
    12.68/13.68=0.93
Predict=HA-MRSA    
      since 0.93>0.614 
2 Logit (p)= -4.095+(1.722*0)+(2.236*0) 
             +(0.021*19)+(1.379*0)=-3.70 
Predicted Prob = 
    0.025/1.025=0.02
Predict=CA-MRSA 
      since 0.02<0.614 
 
 
In order to test the symmetry of matching between the PFGE result and the new Predict 
result, these two variables were compared through McNemar’s test.  The results (test 
statistic= 0.667, p=0.54) revealed that if misclassifications occur, the two methods 
misclassify subjects in a balanced way, equally in both directions. 
 Discriminant analysis has been reported to be less preferable compared to logistic 
regression in situations where observations are classified on the basis of categorical 
variables [Press and Wilson, 1978 and SAS® Users Guide].  In spite of this caveat, this 
analysis was conducted and revealed similar best model and classification results as the 
logistic regression and ROC curve analyses.  The total error rates from the discriminant 






 The goal of this research was to improve classification of MRSA infections as 
healthcare- or community-associated using multivariable statistical methods, in contrast 
to the currently employed classification schemes; healthcare risk factor, infection type, or 
susceptibility pattern.  HA- and CA-MRSA infections often present among disparate age 
groups and in individuals with different risk factors.  They are distinct in the types of 
infections they cause, their transmission risk, and in the different treatment modalities 
they require [11, 22-25].  A more efficient method of discrimination between HA- and 
CA-MRSA, in the absence of PFGE results, could allow for more prompt and effective 
transmission prevention and risk intervention efforts. 
This study dataset of 244 cases is similar by gender, race, and age to the total 
Michigan MRSA Surveillance dataset of 2,151 cases from which it was selected.  
However, the subset has more cases with hospitalizations, deaths, and preexisting 
illnesses relative to the total dataset.  This is likely due to the greater proportion of 
healthcare-associated cases in the subset, because of the greater probability that 
healthcare facilities had cultures available for submission from reported cases.  Obtaining 
cultures for cases reported from the community setting proved more difficult.  The results 
from this investigation are not affected by a proportional difference between HA-MRSA 
and CA-MRSA, because the numbers are sufficiently high in both category types to draw 
distinctions and make comparisons. 
MRSA infections in this study dataset of 244 cases are defined as HA or CA by 
PFGE result (Table 3.1).  The demographic, clinical, and microbiologic variables reveal 




literature, according to the differing presentations of these two MRSA types [10-13, 22-
26].  Individuals at increased risk for acquisition of HA-MRSA are generally older, often 
with weaker immune systems and more preexisting illnesses. Their medical problems 
may require frequent visits and treatments at healthcare facilities, and they often end up 
with systemic, resistant infections.  CA-MRSA usually affects otherwise healthy 
individuals with no preexisting illnesses and tends to mostly cause skin and soft tissue 
infections.  The non-significant difference between HA and CA groups in this study 
dataset for surgical site infections and “wound” infections is likely due to the low 
numbers of surgical site infections and to the vagueness of the term “wound” infection, 
which is generically used to describe infections in both healthcare and community 
settings.  The majority of both HA and CA infections were among white subjects, but 
among blacks the proportions of CA infections were significantly higher than HA 
infections.  These results correspond with other studies that have shown an increased risk 
for CA-MRSA infections and colonization in blacks [27-29]. 
 A number of variables were considered in the development of the new model to 
more accurately define MRSA infections as HA or CA, using PFGE result as the gold 
standard for comparison.  Four variables were chosen for the final model, and three of the 
seven tested variables were eliminated during the analytic selection process.  The 
classification variables infection type and susceptibility pattern were selected along with 
age and hospitalized for inclusion in this new model.  The additional inclusion of age and 
hospitalized is not too surprising as the age distributions for HA- and CA-MRSA 
infections have been shown to be unique from one another [30-33] and hospitalization is 




existing differences between the HA and CA groups for each of these four variables, 
along with the high likelihood that the easily obtained data are accurate, makes them 
strong contributors to the new categorization model.  It is likely that the preexisting 
illnesses variable was eliminated from the model because it is generally difficult to 
consistently obtain an accurate history on patients, as it is to obtain information on 
healthcare risk factors.  As the prevalence of CA-MRSA in the community setting 
continues to increase, an individual with healthcare risk factors could be at greater risk 
for acquisition of CA-MRSA from their community than risk for acquisition of HA-
MRSA from the healthcare settings with which they interact.  Although healthcare risk 
factor wasn’t included in the model, this model serves as a proxy measure for this 
information, and includes variables that are easier to obtain accurately.  As long as the 
delineation exists between the common settings for HA- and CA-MRSA, this information 
from the new model will help identify where an infection was most likely acquired, 
which is pertinent knowledge for appropriately targeting infection control and 
transmission prevention efforts.  The survival variable (died during time of MRSA 
infection) was also eliminated from the best model.  It could represent severity of the 
infection, like the hospitalized variable, however only a small number of all HA-MRSA 
infections die and often deaths attributed to MRSA are not coded accurately [34].  
Therefore, its usefulness as a contributing predictor in the model is not as strong as 
hospitalized.  The data reported for hospitalized during time of MRSA infection and 
survival during time of MRSA infection serve as proxy measures within the time frame 




and of the survival variable to be a contributing predictor at all may be stronger if the 
data collected for these variables were strictly due to MRSA. 
These analyses were run to predict the probability of HA from the dichotomous 
PFGE outcome variable HA (1) and CA (0).  The HA vs. CA outcome for these analyses 
made the sensitivity/specificity analysis slightly more complicated than with a disease/no 
disease outcome.  The sensitivity for a HA-MRSA case is the specificity for a CA-MRSA 
case and the sensitivity for a CA-MRSA case is the specificity for a HA-MRSA.  The 
ROC curve (Figure 3.3) shows that there is no point from this dataset that would give an 
equal sensitivity and specificity for both HA- and CA-MRSA infections.  At the chosen 
optimum cutpoint, the sensitivity for defining a true HA-MRSA case is 93.6%, but the 
sensitivity for defining a CA-MRSA case is 80.3%.  These results are explained by 
Figure 3.2.  The plot of the logit result from the best model shows that the HA-MRSA 
cases are clustered tightly and only a few lie outside of this cluster.  In contrast, the CA-
MRSA cases are more dispersed and a larger number are scattered across the HA-MRSA 
values.  Therefore, the ability to accurately identify a HA-MRSA case is greater than the 
ability to accurately identify a CA-MRSA case. 
 This investigation to identify a new method of MRSA categorization has some 
limitations.   The number of cases used in this model building (n=244) was relatively 
small, due to a limited number of available PFGE results among the total cases reported 
(N=2,151).  Additionally, observations with missing values were excluded from the 
analyses resulting in smaller sample sizes (See Table 3.3: range based on the analysis run 
n=204-244).  Use of a larger sample size in the analyses would increase the power to 




model equation was developed from data collected through voluntary Michigan MRSA 
surveillance conducted in 2005.  Consequently, it would be helpful to rerun these 
analyses with a larger, updated Michigan dataset for validation.  These data are 
considered to be representative of the range of residents who acquire MRSA infections in 
Michigan, although they may not be representative of MRSA infections in other areas.  It 
must be determined whether the best model identified in this research is appropriate for 
other areas of the nation.  A reasonable next step would be to repeat the presented 
analyses with large datasets from other states, and if possible, with a national MRSA 
dataset.  The methods used to develop this model incorporate common and widely 
utilized statistical analyses, so it would be feasible to repeat the steps of model 
development using data from other areas.  The HA- and CA-MRSA profiles are 
constantly changing and the settings where these infections are identified increasingly 
intersect [35-37].  Therefore, this cannot be a static model, but must be continually 
updated and revised to account for differences and changes in MRSA profiles.  In spite of 
the limitations, the new proposed model identifies a combination of basic variables 
already acknowledged and widely used in differentiating HA- from CA-MRSA 
infections, and is likely to improve on the accuracy of categorizing MRSA infections in 
and outside of Michigan.   
 In conclusion, the analyses of this investigation have identified a new 
multivariable model to define MRSA infections as HA or CA.  Individually the variables 
have all been long recognized to relate to MRSA infection, but the use of the four 
covariates (infection type, susceptibility pattern, age, and hospitalized) in combination in 




MRSA.  This model can provide a fast and accurate way for a healthcare system or health 
department to identify MRSA infections as HA or CA.  Knowing which type of MRSA is 
causing infections provides greater opportunity for the most accurate and targeted 
educational messages to patients and caregivers for control of transmission.  This is 
critical to successful prevention programs aimed at controlling increasing resistance and 
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Table 3.1. Michigan MRSA Infections Classified by PFGE Result as Healthcare-






Total N=244 N=159 (65%) N=85 (35%)  
 n (%) n (%)  
Gender: Male 83 (52) 47 (55) 0.6445 
Race: White 107 (82) 44 (63) 0.0083 
          Black 19 (15) 20 (29)  
          Other 4 (3) 6 (8)  
Age   0-80+ 155 (=60 s.d.=22) 82 (=36 s.d.=21) <0.0001 
Hospitalized: Yes 138 (88) 38 (49) <0.0001 
Survival: Died 18 (12) 3 (4) 0.0506 
Preexisting Illness(s):    
          None 9 (6) 12 (17) 0.0069 
          Diabetes Mellitus 65 (41) 14 (19) 0.0012 
          Chronic Renal Insufficiency 30 (19) 5 (7) 0.0175 
          Cardiovascular Disease 46 (29) 5 (7) 0.0002 
          Coronary Heart Failure 38 (24) 6 (8) 0.0047 
          COPD 48 (31) 6 (8) 0.0002 
          Any Underlying Illness 148 (94) 57 (83) 0.0054 
Healthcare Risk Factors:    
          Hospitalized >48 hours 44 (28) 2 (2) <0.0001 
          In ICU >48 hours 21 (13) 2 (2) 0.0057 
          Hospitalized in Prior Year 96 (60) 30 (35) 0.0002 
          Surgery in Prior Year 55 (35) 18 (21) 0.0292 
          Indwell Device in Prior Yr 55 (35) 8 (9) <0.0001 
          LTC/Rehab in Prior Year 40 (25) 8 (9) 0.0032 
Infection Type:    
          Bacteremia 23 (16) 1 (1) 0.0010 
          Pneumonia 42 (29) 6 (8) 0.0003 
          Skin / Soft Tissue 23 (16) 53 (69) <0.0001 
Drug Resistance:    
          Ciprofloxacin 20 (95) 4 (33) 0.0003 
          Clindamycin 99 (83) 8 (14) <0.0001 
          Levofloxacin 142 (93) 23 (28) <0.0001 
* p-values shown are from χ2 tests for categorical variables, Fisher’s exact test for 



















Figure 3.1. Age Group Distribution for Michigan MRSA Infections Classified by PFGE 

































Table 3.2. Comparisons of PFGE Results by Healthcare Risk Factor, Infection Type, and Susceptibility Pattern for Michigan 















81% 59% 79% 63% 0.6201 
Infection 
Type 
84% 69% 84% 70% 1.0000 
Susceptibility 
Pattern 










Table 3.3. Logistic Regression Results with PFGE Result as Outcome Variable for Michigan MRSA Infections Classified as 




Risk Factors  
p-value
Infection 
Type      
p-value
Susceptibility 
Pattern       
p-value



















<.0001 --- --- --- --- --- --- 275.90 0.206 0.3002 
2 
(n=224) 
--- <.0001 --- --- --- --- --- 224.39 0.343 0.2341 
3 
(n=239) 
--- --- <.0001 --- --- --- --- 212.61 0.460 0.2049 
4 
(n=224) 
0.0004 <.0001 --- --- --- --- --- 211.94 0.399 0.2263 
5 
(n=239) 
0.008 --- <.0001 --- --- --- --- 205.86 0.486 0.2049 
6 
(n=221) 
--- <.0001 <.0001 --- --- --- --- 176.90 0.532 0.1721 
7 
(n=221) 
0.189 <.0001 <.0001 --- --- --- --- 175.23 0.539 0.1721 
8 
(n=215) 
--- <.0001 <.0001 0.012 --- --- --- 158.65 0.581 0.1311 
9 
(n=217) 
--- <.0001 <.0001 --- 0.0005 --- --- 163.09 0.571 0.1601 
10 
(n=213) 
--- <.0001 <.0001 --- --- 0.372 --- 167.52 0.543 0.1646 
11 
(n=221) 
--- <.0001 <.0001 --- --- --- 0.040 172.79 0.548 0.1604 
12 
(n=204) 
--- <.0001 <.0001 0.129 0.005 0.206 0.433 138.81 0.625 0.1277 
13 
(n=204) 
--- <.0001 <.0001 0.040 0.002 0.229 --- 139.42 0.622 0.1275 
14 
(n=211) 
--- <.0001 <.0001 0.024 0.004 --- --- 147.93 0.607 0.1448 
Note: See text for variable definitions.  The Wald Global χ2 p-values for all logistic regression models above (1-14) were <0.0001. 
 
Figure 3.2. PFGE result predicting the probability of HA (vs. CA) infection by logistic 
regression with predictors including infection type, susceptibility pattern, age, and 
hospitalized. 

















Figure 3.3. ROC curve output from best logistic model identified to predict the dependent 
variable PFGE result=HA.  This model included infection type, susceptibility pattern, 
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The goal of the discriminant analysis was to minimize the error rate.  Procedures 
run in the discriminant analysis using the same variables that were tested in the logistic 
regression models revealed very similar results.  Susceptibility pattern alone decreased 
the error rate by a greater amount than infection type, which was better then healthcare 
risk factor (Models 1-3).  The three classification variables were tested in pairs, and 
infection type and susceptibility pattern were the best combination (Models 4-6).  
Healthcare risk factor variable was added to the model with infection type and 
susceptibility pattern with no change in the error rate, therefore it was not necessary in 
the model (Model 7).  Age, hospitalized, survival, and preexisting illnesses were tested in 
the model alone with infection type and susceptibility pattern.  Each of these variables 
did decrease the error rate, though age and hospitalized were most effective, and survival 
was least effective (Models 8-11).  All four of the additional variables were tested 
together in the base model with infection type and susceptibility pattern and the error rate 
did decrease a good deal (Model 12).  The preexisting illnesses variable was removed 
with very little change in the error rate (Model 13).  The survival variable was removed 
with only a small increase in the error rate noted (Model 14).  Discriminant analysis, 
therefore, showed similar findings and best model identification as reported from logistic 
regression analysis.  Discriminant analysis was run to predict whether a case was HA-
MRSA or CA-MRSA using the data from the 244 cases in the best model and results 
were very similar to the ROC curve analysis.  The cutpoint identified from the data 
output in the discriminant analysis matched to a ROC probability point of 0.603, which 





curve analysis.  When the predict results from the ROC curve analysis were plotted 
against the discriminant analysis results, only four cases were discordantly identified as a 
HA- or CA-MRSA infection out of the 211 analyzed with no missing variables 
(Appendix Figure 3.1).  In order to verify an accurate match between the PFGE result and 
the discriminant result, these two variables were compared through McNemar’s test.  The 
results (test statistic=1.96, p=0.23) showed that if misclassification occurs, the two 
methods misclassify in a similar way. 
 
Appendix Figure 3.1. Probability of healthcare-associated (HA) categorization versus 
probability of community-associated (CA) categorization for ROC Predict results and 
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Profile of Healthcare- and Community-Associated Methicillin-Resistant 




 Background: A variety of classification schemes have been used to define 
methicillin-resistant Staphylococcus aureus (MRSA) infections as either healthcare-
associated (HA) or community-associated (CA).  Three of the most common methods 
(healthcare risk factor, infection type, susceptibility pattern) have been shown to produce 
discordant results when compared.  We have previously developed a new classification 
model (Chapter III) to more accurately define MRSA as HA or CA, which closely 
approximates pulsed-field gel electrophoresis (PFGE) categorization.  The variables 
included in this new model are infection type, susceptibility pattern, age, and 
hospitalization during the time of infection.  This current investigation demonstrates the 
improved accuracy of the multivariable classification model and uses the new model to 
better define the epidemiology of MRSA infections in Michigan. 
Methods: MRSA infections were voluntarily reported in Michigan to the 
Michigan Department of Community Health (MDCH) between October 1, 2004 and 
December 31, 2005.  Data on patient demographics, risk factors, and infection 
information were recorded on the MDCH MRSA Surveillance Case Report Form and 





were classified as HA or CA using PFGE test result when available, or alternatively using 
the new model that was identified to accurately predict MRSA type, in the absence of 
PFGE result.  A total of 1,644 cases were included in these analyses. 
Results: MRSA infections were more accurately defined as HA or CA using the 
new multivariable model compared to classification by healthcare risk factor alone.  The 
results help to clarify the existing differences in risk factors, infection types, outcomes, 
and resistance patterns between HA- and CA-MRSA in Michigan and highlight the risk 
groups and facility types most in need of targeted MRSA control and prevention efforts.  
The greatest proportion of MRSA reports were submitted from hospital and correctional 
facilities.  The CA-MRSA group had higher proportions of males and blacks compared to 
the HA-MRSA group.  These data also show that MRSA is prevalent throughout 
Michigan and in a variety of geographic regions.  The approximate MRSA prevalence 
estimates calculated for three Michigan healthcare systems and their surrounding 
catchment areas ranged from 94-196/100,000 persons. 
Conclusion: The MRSA surveillance data collected has made possible this first 
report on HA- and CA-MRSA infections from throughout Michigan.  The results, 
obtained using a new multivariable model to classify MRSA infections as HA or CA, 
provide a practical picture of the overall epidemiology of MRSA in Michigan.  This 
information can be used to initiate more accurately targeted control efforts and 
educational prevention messages, in order to effectively combat this adept organism.  The 
Michigan MRSA profile will continue to evolve, and so it is crucial that efforts to track 






 Methicillin-resistant Staphylococcus aureus (MRSA) infections have been 
categorized in a number of different ways based on various epidemiologic, clinical, and 
molecular criteria.  One widely used classification differentiates between healthcare-
associated (HA) and community-associated (CA) infections.  MRSA occurring in 
healthcare settings or in individuals who received recent or continuous care in such a 
setting is referred to as healthcare-associated MRSA (HA-MRSA).  MRSA identified 
among individuals outside of a healthcare venue and/or who have not received recent 
care in that setting is referred to as community-associated MRSA (CA-MRSA).  HA-
MRSA has been endemic in large urban medical centers in the U.S. since the 1990s [1-5] 
and CA-MRSA has greatly increased in prevalence since the late 1990s [6-15].  These 
two types of MRSA have emerged as distinct organisms with differing epidemiologic 
profiles in terms of risk factors, infection type presentations, and susceptibility patterns 
[16-26].  It is important to be able to accurately differentiate between these two types of 
MRSA infection, in order to treat people with proper antimicrobial therapy, respond with 
appropriate infection control precautions, and use the correct transmission prevention 
guidelines. 
 Pulsed-field gel electrophoresis (PFGE) testing can be considered a gold standard 
for distinguishing between HA- and CA-MRSA infections [27]. This molecular strain 
typing requires at least three days to perform, is expensive, calls for specialized 
laboratory training, is not readily available in most clinical laboratories, and doesn’t 
consider patient details.  Classifying HA- vs. CA-MRSA based on healthcare risk factor, 





these methods are regularly used by healthcare providers and researchers.  However, 
these three criteria for differentiating HA and CA have been shown to produce discordant 
results when compared, making their use problematic [16, 17, 20, 22-26]. 
MRSA has been studied extensively.  Approximately 6,730 related articles 
appeared on a PubMed MRSA search.  Many of these articles include information on the 
differences between HA-MRSA and CA-MRSA infections.  Most such research is 
derived from planned research projects, reports on outbreak investigations, or based on 
surveillance at sentinel sites.  Currently, limited population-based data, collected and 
reported through systematic public health surveillance for MRSA infections are available.  
The reasons include limited availability of funding, the difficulty in tracking and 
reporting large numbers of HA-MRSA in hospitals, and challenges in identifying CA-
MRSA from community settings.  Consequently, most of the population-based data on 
HA- and CA-MRSA infections are reported from nine U.S. states (CA, CO, CT, GA, 
MD, MN, NY, OR, TN) that participate in the Active Bacterial Core Surveillance 
(ABCs) in the Emerging Infections Program through the Centers for Disease Control and 
Prevention (CDC) [28-35].  These sites received considerable funding allowing them to 
conduct surveillance (including for MRSA) that most other state health departments and 
healthcare facilities could not handle due to lack of resources, staff and money.  
Laboratory reports of positive MRSA cultures from normally sterile body sites are 
actively identified and epidemiologic patient data are collected and reported from the 
residents of defined catchment areas from each of these program sites.  This surveillance 
has revealed that prevalence and incidence rates, groups at highest risk for acquisition, 





organisms depending on the geographic area of the nation.  Michigan is not part of this 
funded surveillance program and statewide characterization data do not currently exist, 
despite a significant impact from HA- and CA-MRSA in this region.  This has been noted 
from the frequently large number of reported MRSA outbreaks and inquiry calls to the 
Michigan Department of Community Health (personal communication). 
Effective control and prevention of both HA- and CA-MRSA infections in 
Michigan require a thorough epidemiological characterization of the problem.  It is 
critical to clarify and understand the Michigan MRSA profile by gender, race, age, 
preexisting medical conditions, healthcare risk factors, types of infections, and 
susceptibility profiles.  With this information, Michigan healthcare providers and public 
health professionals can be more adequately informed to appropriately implement 
effective infection control procedures within facilities and communities and accurately 
educate patients and residents in order to interrupt and prevent further transmission of 
MRSA. 
The purpose of this investigation was to better define the epidemiology of MRSA 
infections in Michigan and expand upon the current population-based profile of MRSA 
presented in other regions of the nation.  Michigan’s MRSA infections are classified as 
HA or CA using a PFGE test when available, or alternatively using a new less resource 
intensive model that we developed to classify MRSA type as HA or CA, in the absence 
of PFGE results.  The epidemiology of these Michigan HA- and CA-MRSA infections 
are then presented and compared.  We compared categorization of HA and CA using 
PFGE result or results generated from the multivariable model to classification based on 





methods and to define the groups that were classified inconsistently.  Data from three 
healthcare systems of Michigan were used to estimate and compare MRSA prevalence in 




 MRSA surveillance was conducted by the Michigan Department of Community 
Health (MDCH) from October 1, 2004 through December 31, 2005.  Surveillance was 
carried out as a designated medical research project for public health purposes, which 
permits collection of data of public health significance without having to revise the 
reportable disease list to make this reporting mandatory.  Thus more specific data from 
both HA-MRSA and CA-MRSA infections were collected by public health authority.  
Data submission for individual MRSA cases under this designation was voluntary, 
although the reporting of MRSA outbreaks is legally required in Michigan.  The medical 
research designation protects the submitted data and the submitter under the Public 
Health Code (MCL 333.2631-2635), so that confidentiality and appropriate use are 
guaranteed.  Hence, the data are protected and inadmissible as evidence in a court, and 
the submitter is protected from liability for furnishing the data.  This research project was 
approved by the MDCH Chief Medical Executive and the MDCH Human Subjects 
Committee, as well as the University of Michigan Institutional Review Board.  The 
request to report individual MRSA cases to MDCH was announced statewide via letters, 
updates to reporting guidelines, and presentations to healthcare providers, laboratories 





were voluntarily reported through local health departments to the MDCH Antimicrobial 
Resistance Epidemiologist.  Information was submitted using a two-page MDCH MRSA 
Surveillance Case Report Form and laboratory susceptibility test result sheets. 
 A total of 2,227 unduplicated MRSA cases were reported to the MDCH by 
correctional facilities, private physicians, infection preventionists, hospital laboratories, 
and local health departments throughout Michigan from October 1, 2004 through 
December 31, 2005.  Seventy-six cases (3.4%) were excluded due to: non-MI residence 
(n=19), infection type specified as none (n=54) or colonization (n=3).  This left 2,151 
unique cases in the total Michigan MRSA infection surveillance dataset.  An additional 
507 (23.6%) of MRSA cases had data missing for the variables required in the new 
classification model and were deleted during the analyses.  Therefore, 1,644 Michigan 
MRSA infections were analyzed in this study. 
Data Management 
 The CDC used PFGE to characterize a large number of domestically occurring 
MRSA isolates and establish a national database of PFGE patterns in 2003.  Eight 
lineages were originally identified from these isolates and were designated as pulsed-field 
types (PFT) USA100 through USA800 [27, 36].  PFT information through PFGE testing 
was available on a random selection of 244 of the 1,644 cases in the study dataset (see 
Chapter III).  This subset of 244 cases was previously used in the analyses to develop a 
new statistical model to more accurately classify an MRSA infection as HA or CA.  The 
PFT results from the 244 MRSA infection isolates were used to categorize cases as either 
HA or CA according to the definitions of the PFT established by the CDC [27].  Cases 





Cases identified as USA300 or USA400 were defined as CA-MRSA.  PFTs USA500 and 
USA700 were not represented in the 244 PFGE results. 
 The 1,400 cases without a PFGE result in the study dataset were categorized as 
HA- or CA-MRSA using the newly developed multivariable model to classify MRSA 
type.  This model collectively incorporates the following variables: infection type, 
susceptibility pattern, age, and hospitalized as a basis for MRSA classification.  Infection 
type and susceptibility pattern were defined for each of the 1,400 reported MRSA cases.  
Cases were labeled as CA-MRSA on the basis of infection type if a skin or soft tissue 
infection was diagnosed, including abscess, cellulitis, folliculitis, and impetigo, or if a 
wound infection had “skin” identified as the culture site.  Cases with other and more 
serious infections, including bacteremia, meningitis, osteomyelitis, pneumonia, septic 
arthritis, and surgical site infection were labeled as HA-MRSA.  CA-MRSA may in some 
situations cause more serious infections like pneumonia or bacteremia, but these 
infections are more typically caused by HA-MRSA and are usually accompanied by the 
HA-MRSA risk factors previously listed [18, 31].  Therefore, if a case had both a skin or 
soft tissue infection and more invasive infection concurrently, it was considered HA-
MRSA to give more weight to the more serious infection type.  Only 13 cases met this 
criterion with either skin/soft tissue infection and bacteremia (n=8) or skin/soft tissue 
infection and pneumonia (n=5) present simultaneously. 
Cases were labeled as CA-MRSA on the basis of susceptibility pattern if their 
isolates were resistant only to β-lactams, including cephalosporins and carbapenems.  
This is the basic resistance pattern that defines MRSA [37].  Cases were labeled as HA-





cephalosporins and carbapenems, were also reported.  This higher level resistance 
included, but was not limited to, aminoglycosides, folate pathway inhibitors, 
lincosamides, fluoroquinolones, and tetracyclines.  Erythromycin, a macrolide, was not 
used in the susceptibility pattern categorization, based on research showing increased 
CA-MRSA resistance to erythromycin [23, 27, 38] and the large overall proportion of 
erythromycin-resistance in the Michigan dataset. 
Data Analysis 
 The study dataset of 1,644 MRSA infections was categorized as HA(1) or CA(0) 
by either PFGE result (n=244 cases) or Predict result (n=1,400 cases).  A Predict result 
was generated for the 1,400 cases by classifying cases using the new multivariable model 
developed in a previous investigation of the Michigan MRSA dataset. 
The model equation is: 
Logit (p) = -4.095 + (1.722*Infection Type) + (2.236*Susceptibility Pattern) +    
               (0.021*Age) + (1.379*Hospitalized) 
 
Age is a continuous variable, Hospitalized is yes/1 or no/0, Infection Type and 
Susceptibility Pattern are HA/1 or CA/0 based on previously explained definitions. 
 
Predicted Probability = [exp(Xβ) / 1+exp(Xβ)] 
 
If Predicted Probability >= 0.614 then Predict = HA-MRSA 
 
If Predicted Probability < 0.614 then Predict = CA-MRSA 
 
Univariate analyses were conducted to provide a comparison of the demographic 
and clinical patterns of HA-MRSA versus CA-MRSA infections when classified by 
either PFGE or Predict result.  Frequencies, percentages, and distributions of HA-MRSA 
and CA-MRSA infections are reported by gender, race, age, county of residence, 





of MRSA infection, preexisting medical conditions, healthcare risk factors, infection 
type, and susceptibilities to specific antimicrobial agents.  Chi-square and Fisher’s exact 
tests (when expected cell frequencies were <5) were performed on categorical variables 
to test for significant differences in proportions between HA-MRSA and CA-MRSA 
defined cases.  The t-test was used to make the comparison between HA-MRSA and CA-
MRSA cases for the continuous age variable. 
The 1,644 cases in the study dataset were also categorized as HA- or CA-MRSA 
by the healthcare risk factor classification scheme.  Cases were labeled as HA-MRSA on 
the basis of healthcare risk factor if they had at least one of the following established risk 
factors: were hospitalized >48 hours prior to the current infection (i.e., patient was not 
MRSA-infected at time of hospitalization but culture and infection were identified > 48 
hours after admission), were in an intensive care unit (ICU) >48 hours prior to the current 
infection, were hospitalized in the previous year (i.e., admitted and discharged from a 
hospital at any time during the year prior to the current infection), had surgery in the 
previous year, received dialysis in the previous year, had a percutaneous device or 
indwelling catheter in the previous year, or if they resided in a long-term care (LTC), 
nursing home or rehabilitation facility in the previous year [29, 39, 40].  Cases with “no” 
reported for all seven HA-MRSA risk factors (i.e., had none of the established risk 
factors) were considered CA-MRSA by default. 
The HA and CA outcomes from categorization of the study dataset by healthcare 
risk factor were compared to the classification according to PFGE or Predict result to 
identify discordant classification.  Univariate analyses were conducted to provide a 





infections when classified by healthcare risk factor as done with Predict and PFGE 
results.  The frequencies, percentages, and distributions of healthcare risk factor defined 
HA-MRSA and CA-MRSA infections as reported by gender, race, age, hospitalized 
during time of MRSA infection, survival during time of MRSA infection, preexisting 
medical conditions, infection type, and susceptibilities to specific antimicrobial agents 
were compared to results when the same 1,644 cases were classified as HA or CA by 
Predict or PFGE result. 
MRSA prevalence estimates were calculated for three zip code-delimited areas of 
Michigan, representing healthcare system catchment areas. MRSA infections were 
consistently reported during the entire period of the surveillance project from three 
healthcare systems, which are located in the southwest, west side, and suburban southeast 
regions of Michigan.  The population represented from the southwest region is widely 
dispersed and includes a smaller urban area with surrounding rural area.  The west side 
region is mostly a large urban area with some surrounding rural area.  The southeast 
region is a small suburban area outside a large city.  Catchment areas were drawn around 
each healthcare system, considering distance and bed size of surrounding, competing 
healthcare facilities [MDCH, unpublished data], and the estimated catchment area 
populations were based on the 2000 U.S. Census.  Prevalence for each healthcare system 
and its catchment area was estimated as the number of MRSA cases reported in 2005 
divided by the estimated population of the catchment area.  Confidence intervals were 
calculated based on the Poisson distribution.  All statistical analyses were conducted 
using SAS® statistical software (SAS System for Windows V9.1.3, SAS Institute Inc., 






 A total of 1,644 cases were analyzed, of which 937 (57%) were male.  The 
race/ethnicity distribution was 993 (60%) white, 323 (20%) black, 67 (4%) “other” (i.e., 
Hispanic/Latino, American Indian/Alaskan Native, Asian, or Native Hawaiian/Pacific 
Islander), and 261 (16%) unknown.  The mean age was 45 years old (s.d.=24 years).  In 
this population, 661 (40%) were hospitalized during time of MRSA infection, 71 (4%) 
died during time of MRSA infection, 1,172 (71%) had at least one preexisting illness, 
while 281 (17%) were reported having no preexisting illnesses with 191 (12%) unknown. 
 There were 601 cases (37%) defined as HA-MRSA, 159 by PFGE and 442 by 
Predict (Table 4.1).  The other 1,043 cases (63%) were defined as CA-MRSA, 85 by 
PFGE and 958 by Predict (Table 4.1).  More males than females had CA-MRSA 
infections, yet this gender distribution was the same among HA-MRSA infections 
(p<0.0001).  The higher proportion of whites was in the HA-MRSA group, but the higher 
proportion of blacks was in the CA-MRSA group (p<0.0001).  The mean age for HA-
MRSA infections was 65 years old (s.d.=19 years), and for CA-MRSA was 34 years old 
(s.d.=19 years) (p<0.0001).  The highest proportions of HA-MRSA infections were 
reported among those 50 years and older, while the highest proportions of CA-MRSA 
infections were reported among those younger than 50 years old (p<0.0001) (Figure 
4.1a).  Figure 4.1b shows the number of reported MRSA infections age-adjusted 
according to 2000 U.S. Census data, and reveals very similar distribution curves for the 
HA- and CA-MRSA groups.  Seventy-six percent of the individuals with HA-MRSA 
infections were hospitalized, while 20% with CA-MRSA were hospitalized during time 





time of MRSA infection compared to only 1% with CA-MRSA (p<0.0001).  HA-MRSA 
infected individuals suffered from more preexisting illnesses than those with CA-MRSA, 
including diabetes mellitus, chronic renal insufficiency, dialysis (p=0.0002), 
cardiovascular disease, coronary heart failure, chronic obstructive pulmonary disease, and 
overall “any” preexisting illness (for each illness not previously specified, p<0.0001).   
People with HA-MRSA infections were more likely to have been hospitalized 
>48 hours prior to the current infection, in an ICU >48 hours prior to the current 
infection, hospitalized in the previous year, had surgery in the previous year, received 
dialysis in the previous year, had a percutaneous device or indwelling catheter in the 
previous year, and/or resided in a LTC, nursing home or rehabilitation facility in the 
previous year compared to those with CA-MRSA (for each risk factor, p<0.0001).  Of the 
five most common infection types analyzed, people with CA-MRSA were most likely to 
have skin or soft tissue infections (p<0.0001), while those with HA-MRSA suffered from 
bacteremia, pneumonia, and surgical site infections (for each infection type, p<0.0001).  
The proportion of individuals with “wound” infections did not differ significantly 
between the HA- and CA-MRSA groups (p=0.479).  Of the non-β-lactam drugs 
evaluated, the HA-MRSA infected group was more likely to be resistant to ciprofloxacin, 
clindamycin, gentamicin, levofloxacin, and trimethoprim-sulfamethoxazole (for each 
drug, p<0.0001) compared to the CA-MRSA group. 
The number of voluntarily reported MRSA infections by the patient’s county of 
residence is shown in Figure 4.2.  These numbers do not indicate prevalence or incidence 
as case submissions were voluntary, level of participation varied, and in some areas the 





active surveillance for MRSA cases, therefore resulting in better reporting in those 
jurisdictions.  Seventy-two percent of the MRSA infections were reported from hospital 
settings, followed by 18% from correctional facilities, and 6% from outpatient settings 
(Figure 4.3).  Almost all of the HA-MRSA cases and close to two-thirds of the CA-
MRSA cases were reported from hospital settings (92% and 61%, respectively).  One-
third of the CA-MRSA cases were reported from correctional facilities and outpatient 
settings (26% and 8%, respectively).  Only two percent of all the MRSA case reports 
originated from local health departments, although, in many instances, the health 
department received initial MRSA infection reports from the other settings and dedicated 
much time and effort to assist with case follow-up. 
 Concordance/discordance of HA- or CA-MRSA classification by PFGE or Predict 
result versus classification by healthcare risk factor indicated that 376 (23%) of the 
MRSA infections would be classified differently (HA or CA) if the single classification 
variable healthcare risk factor were used instead of the new statistical classification 
model Predict result (311 cases) or PFGE result (65 cases) (Table 4.2).  Results from the 
descriptive variables whose distributions by healthcare risk factor classification differ 
within HA/CA categories compared to classification by PFGE or Predict result are shown 
in Table 4.2a.  There were 699 (43%) cases defined as HA-MRSA by healthcare risk 
factor and 945 (57%) cases defined as CA-MRSA.  More MRSA infections were 
classified as HA using the healthcare risk factor categorization scheme.  The group of 
109 individuals that were classified as CA-MRSA by healthcare risk factor and HA-
MRSA by Predict result has a higher proportion of whites (84%), a much older mean age 





proportion of skin and soft tissue infections (%23), and much higher resistance to 
ciprofloxacin, clindamycin, and levofloxacin (86%, 54%, 80%, respectively) compared to 
overall categorization as CA-MRSA by either healthcare risk factor or Predict result.  The 
group of 202 individuals that were classified as HA-MRSA by healthcare risk factor and 
CA-MRSA by Predict result has a higher proportion of blacks (25%), a younger mean 
age (=41 years old), a much lower proportion of hospitalized individuals (27%), a 
similar proportion of hospitalizations in the previous year (62%), a very high proportion 
of skin and soft tissue infections (%77), and much lower resistance to ciprofloxacin, 
clindamycin, and levofloxacin (32%, 25%, 29%, respectively) compared to overall 
categorization as HA-MRSA by either healthcare risk factor or Predict result. 
 Data used to calculate the prevalence estimates for three Michigan healthcare 
systems and their catchment areas are presented in Table 4.3.  Estimates of MRSA 
prevalence per 100,000 population indicate 94 for the southeast area, 196 for the 
southwest area, and 161 for the west side area. 
 
Discussion 
 This study applied a new multivariable classification model to profile MRSA 
infections in the state of Michigan, and demonstrated the validity of this new method in 
the state.  This model was previously developed using a subset of Michigan surveillance 
data that most closely approximated the PFGE categorization result.  Data should be 
representative as they were collected from voluntary surveillance throughout Michigan, 
with some specific facilities and jurisdictions being more able and willing to participate 





and rural areas, as well as healthcare settings (hospitals, outpatient clinics, LTC and 
rehabilitation facilities), correctional facilities, and local health departments.  This sample 
should represent the entire Michigan population, allowing for broad characterization of 
HA- and CA-MRSA infections in this state.  In three areas where all MRSA infections 
were consistently reported, estimation of MRSA prevalence was possible.  Beyond the 
three specific areas, however, the voluntary nature of data collection for this surveillance 
makes estimation of prevalence and incidence rates of MRSA infections impossible for 
any particular reporting facility type, county, or statewide. 
 The HA- and CA-MRSA groups, as classified according to PFGE or Predict 
result, reveal recognized distributions for the demographic, clinical, and microbiologic 
variables that are consistent with those seen in previously published literature, according 
to the differing presentations of these two MRSA types [16, 17, 19, 20, 22-26].  The age 
means and distributions within the HA- and CA-MRSA groups were as previously 
reported.  The number of reported Michigan CA-MRSA infections was highest among 
those ≤ 50 years (mean=34 years).  This group would more likely be younger, healthier, 
and less likely to require healthcare services.  Almost one-third of the CA-MRSA group 
reported having no preexisting illnesses.  HA-MRSA increased as age group advanced 
from youngest to oldest, with the largest increase in number of reports occurring among 
individuals 40-49 years old and a progressive increase thereafter (mean=65).  Similar 
distribution curves were seen after adjusting HA- and CA-MRSA infections by the 
number of Michigan residents within each age group.  Older age increases the likelihood 
of comorbidities and illnesses, and therefore the possibility of more frequent interaction 





and from one-fourth to two-fifths of this group reported having one or more of the six 
serious conditions listed in Table 4.1. 
The proportion of males to females among the HA-MRSA reported infections was 
equal, whereas the proportion of males with CA-MRSA infections was significantly 
higher.  These results correlate with previous studies reporting that a higher percentage of 
men are more likely to engage in “close contact” sports, have more cuts and skin 
abrasions, and live in close congregate settings like military barracks or correctional 
facilities, all previously established risk factors for CA-MRSA [10, 11, 13].  Other 
studies have reported higher prevalence of CA-MRSA infections among males in urban 
settings, men who have sex with men, and drug users [41-44]. 
The overall race/ethnicity distribution for this study population closely matches 
the race/ethnicity distribution of the Michigan population, with only a slightly lower 
proportion of whites and a slightly higher proportion of blacks.  The race/ethnicity 
distribution for HA-MRSA infections closely corresponded to the state’s population 
distribution.  The CA-MRSA infection race/ethnicity distribution reveals a lower 
proportion of whites and higher proportion of blacks compared to the Michigan 
population.  This finding coincides with other studies that have demonstrated an 
increased risk for CA-MRSA infections and colonization among blacks [34, 45-47].  The 
reason for this association remains unclear, but differences in immune response or 
socioeconomic factors (e.g., crowded living or decreased access to medical care), which 
are correlated with black race, may contribute to these findings [29, 48, 49]. 
Three-fourths of the HA-MRSA cases were hospitalized during time of MRSA 





principally due to skin/soft tissue infections which are typically less serious if treated 
appropriately with wound care, incision and drainage, and/or antibiotics, when indicated.  
In contrast, almost half of HA-MRSA cases were associated with pneumonia, bacteremia, 
and surgical site infections, which often require hospitalization for appropriate treatment.  
The non-significant difference between the two groups for “wound” infections is likely 
due to the vagueness of the term, which is generically used to describe infections in both 
healthcare and community settings.  Only a small proportion of the study population died 
during time of MRSA infection, although most of the deaths occurred among the more 
serious HA-MRSA infections (i.e., cases with bacteremia and pneumonia). 
 The HA-MRSA organisms had higher levels of multi-drug resistance compared to 
the CA-MRSA organisms, consistent with many previous studies [1, 2, 17, 21-24, 26].  
Resistance was highest for two common fluoroquinolones, ciprofloxacin and 
levofloxacin, followed by resistance to clindamycin.  Clindamycin resistance could 
potentially be even greater than revealed, since these data did not indicate how often tests 
were performed to identify the presence of inducible clindamycin resistance for 
erythromycin-resistant/clindamycin-susceptible isolates, and there was an overall high 
percentage of erythromycin resistance in this study population.  The continual acquisition 
of resistance genes by HA-MRSA organisms is of serious concern and establishes the 
real possibility of a pan-resistant MRSA organism.  This concern came even closer to 
realization with the report of the first HA-MRSA organism to also acquire resistance to 
vancomycin (VRSA) in 2002, followed by six additional cases through 2006 (Sievert, et 





antimicrobials and the need for the introduction of new antimicrobial classes or a vaccine 
against MRSA. 
CA-MRSA infections identified within healthcare settings have been reported in 
recent years [50-52].  Sixty-one percent of the reported Michigan CA-MRSA infections 
were reported from hospital settings.  These findings highlight the significant disease 
burden that such community infections place on the emergency departments and possibly 
inpatient units of healthcare facilities, also increasing the likelihood for transmission of 
CA-MRSA within such settings.  Correctional facilities also had a high burden of CA-
MRSA infections.  These settings are a recognized as sites for acquisition and 
transmission of CA-MRSA [7-9, 11].  CA-MRSA infections in correctional facilities also 
contribute to transmission in the surrounding communities due to high volumes and 
continual movement of individuals between these two settings.  Individuals in 
correctional settings also increase the likelihood for transmission of CA-MRSA within 
healthcare facilities as they utilize medical services [46]. 
Three classification variables have been commonly used to define MRSA 
infections as HA or CA: healthcare risk factor, infection type, and susceptibility pattern.  
Healthcare risk factor was not included in the new multivariable model that generated the 
Predict result.  The comparisons of HA and CA categorizations by Predict result versus 
healthcare risk factor indicate that of the 109 cases classified as CA-MRSA by healthcare 
risk factor and HA-MRSA by the multivariable model, many are probably not true CA-
MRSA, but are HA-MRSA cases misclassified according to the healthcare risk factor 
scheme due to missing healthcare risk factor data.  Some cases may be true CA-MRSA 





hospitalized, and having more serious infections.  Of the 202 cases classified as HA-
MRSA by healthcare risk factor and CA-MRSA by the multivariable model, many are 
probably not true HA-MRSA, but are CA-MRSA cases misclassified according to the 
healthcare risk factor scheme due to a history of hospitalization in the previous year.  
Some cases may be true HA-MRSA misclassified by the multivariable model as CA-
MRSA due to younger age and not being hospitalized.  There is also the possibility that 
some of the 202 cases are the CA-MRSA strain acquired in the healthcare setting.  
Categorization by the Predict result calculated from the new statistical model considers 
multiple variables (infection type, susceptibility pattern, age, and hospitalized), and 
therefore more accurately classifies the cases as HA- or CA-MRSA.  These results 
underscore some important messages; individuals in Michigan may be more likely to 
acquire CA-MRSA from their community than HA-MRSA from brief interactions with 
healthcare facilities, acquisition of CA-MRSA from interactions with healthcare facilities 
may be likely, and the new multivariable classification model is an accurate method of 
classifying HA- and CA-MRSA infections.  For now, HA- and CA-MRSA are 
distinguishable from one another by molecular make-up, including resistance levels and 
the types of infections each causes.  This scenario allows the multivariable model to serve 
as a proxy measure of HA and CA infections, without having to collect data on healthcare 
risk factors, which is often difficult to obtain accurately.  Collecting data on healthcare 
and community risk factors will, however, become necessary and important to accurately 
classify MRSA infections as HA or CA, if the USA300 strain becomes the most 





Results reveal varying prevalence estimates for all three of the healthcare systems 
and their catchment areas (Table 4.3).  These are only estimates and do not fully 
represent an entire region, or specific delineated areas of Michigan.  MRSA is a statewide 
problem and causes a considerable number of infections throughout Michigan.  Although 
we believe that the numerators accurately represent all cases of MRSA infections from 
the three healthcare systems for 2005, the denominators are only approximate estimates 
of population market share in areas where many healthcare facilities from different 
systems are in close proximity to one another and compete for overlapping populations of 
individuals.  The MRSA prevalence estimates vary between the healthcare system areas, 
but the racial distributions from their catchment areas are quite similar.  Further 
surveillance is needed to obtain more thorough data from a larger number of healthcare 
systems, in order to more accurately estimate the true prevalence of MRSA throughout 
Michigan and to be able to account for any differences between areas. 
The voluntary MRSA surveillance conducted from the fourth quarter of 2004 
through the end of 2005, allowed for this first comprehensive epidemiologic profile of 
MRSA infections in Michigan.  The newly developed multivariable statistical 
classification model provided the ability to more accurately classify these MRSA 
infections as healthcare- or community-associated in the absence of PFGE result.  It is 
clear that MRSA infections are prevalent throughout the variety of geographic areas of 
Michigan.  The groups at highest risk for acquisition of HA- and CA-MRSA infections 
and the settings in most need of targeted interventions are not unique compared to other 
areas of the US.  However, this Michigan-specific data highlights areas of concern for the 





efforts to target correctional facilities, especially jails where individuals remain for 
shorter periods of time and then are released back into the communities.  These results 
also indicate that a large number of CA-MRSA infections are reported from hospital 
settings, and these infections may not stop at the emergency department doors.  
Therefore, Michigan hospitals need to tailor infection control and prevention efforts to 
address both HA- and CA-MRSA organisms, and ensure that surveillance of resistant 
organisms in these settings are capable of identifying further changes in resistant S. 
aureus organisms. 
The Michigan MRSA profile will continue to evolve, and control efforts and 
educational prevention messages must keep up with the changing epidemiology, in order 
to effectively combat these adept organisms.  To this end, it is crucial that public health 
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Table 4.1. Michigan MRSA Infections Classified as Healthcare-Associated (HA) or 
Community-Associated (CA) by PFGE Result (n=244) or Predict Result (n=1,400). 
Demographic/Characteristic Healthcare-Associated Community-Associated p-value* 
Total N=1,644 N=601 (37%) N=1,043 (63%)  
 n (%) n (%)  
Gender: Male 302 (50) 635 (61) <0.0001 
Race: White 406 (80) 587 (67) <0.0001 
          Black 80 (16) 243 (28)  
          Other 20 (4) 47 (5)  
Age   0-80+ 597 (=65 s.d.=19) 1,040 (=34 s.d.=19) <0.0001 
Hospitalized: Yes 453 (76) 208 (20) <0.0001 
Survival: Died 64 (12) 7 (1) <0.0001 
Preexisting Illness(s):    
          None 25 (4) 256 (29) <0.0001 
          Diabetes Mellitus 227 (39) 82 (9) <0.0001 
          Chronic Renal Insufficiency 94 (16) 17 (2) <0.0001 
          Dialysis 25 (4) 11 (1) 0.0002 
          Cardiovascular Disease 163 (28) 56 (6) <0.0001 
          Coronary Heart Failure 139 (24) 22 (2) <0.0001 
          COPD 147 (25) 34 (4) <0.0001 
          Any Underlying Illness 549 (96) 623 (71) <0.0001 
Healthcare Risk Factors:    
          Hospitalized >48 hours 103 (17) 30 (3) <0.0001 
          In ICU >48 hours 55 (9) 11 (1) <0.0001 
          Hospitalized in Prior Year 321 (53) 156 (15) <0.0001 
          Surgery in Prior Year 185 (31) 96 (9) <0.0001 
          Dialysis in Prior Year 33 (5) 14 (1) <0.0001 
          Indwell Device in Prior Yr 185 (31) 62 (6) <0.0001 
          LTC/Rehab in Prior Year 187 (31) 45 (4) <0.0001 
Infection Type: Bacteremia 73 (12) 15 (1) <0.0001 
                          Pneumonia 150 (25) 17 (2) <0.0001 
                          Skin / Soft Tissue 78 (13) 908 (88) <0.0001 
                          Surgical Site 47 (8) 11 (1) <0.0001 
Drug Resistance:    
          Ciprofloxacin 178 (94) 97 (27) <0.0001 
          Clindamycin 344 (78) 103 (15) <0.0001 
          Gentamicin 54 (10) 8 (1) <0.0001 
          Levofloxacin 525 (92) 204 (24) <0.0001 
          Trimeth.-Sulfamethoxazole 16 (3) 4 (0.4) <0.0001 















Figure 4.1a. Age Group Distribution for Michigan MRSA Infections Classified as 
Healthcare-Associated (HA) or Community-Associated (CA) by PFGE Result (n=244) or 































Figure 4.1b. Age-Adjusted Rate Distribution of Reported Michigan MRSA Infections 
Classified as Healthcare-Associated (HA) or Community-Associated (CA) by PFGE 










































Figure 4.2. Number of Michigan MRSA Infections Voluntarily Reported by Patient 






Figure 4.3. Michigan MRSA Infections by Reporting Facility Type and Classified as 
Healthcare-Associated (HA) or Community-Associated (CA) by PFGE Result (n=244) or 






























Table 4.2. Comparison of Michigan MRSA Infections Classified as Healthcare-
Associated (HA=1) or Community-Associated (CA=0) by PFGE Result (n=244) and 








# of Cases Matching 
Row Combination 
Results  [n, %] 
Concordant 1  1 129  (8) 
  1 1 333  (20) 
 0  0 50  (3) 
  0 0 756  (46) 
 Total: 1,268  (77%) 
Discordant 1  0 30  (2) 
  1 0 109  (7) 
 0  1 35  (2) 
  0 1 202  (12) 
 Total: 376  (23%) 




Table 4.2a. Results from Healthcare Risk Factor Classification as Healthcare-Associated 
(HA) or Community-Associated (CA) MRSA that Differ Compared to Classification by 
PFGE Result and Predict Result. 
Demographic/Characteristic Healthcare-Associated Community-Associated p-value* 
Total N=1,644 N=699 (43%) N=945 (57%)  
 n (%) n (%)  
Race: White 453 (76) 540 (69) 0.015 
          Black 118 (20) 205 (26)  
          Other 27 (4) 40 (5)  
Age   0-80+ 695 (=58 s.d.=23) 942 (=35 s.d.=21) <0.0001 
Hospitalized: Yes 442 (63) 219 (23) <0.0001 
Infection Type:  Skin / Soft Tissue 217 (31) 769 (83) <0.0001 
Drug Resistance:    
          Ciprofloxacin 162 (75) 113 (34) <0.0001 
          Clindamycin 322 (67) 125 (19) <0.0001 
          Levofloxacin 487 (77) 242 (31) <0.0001 





Table 4.3. Approximate Prevalence Estimates for Three Healthcare Systems and Their 
Catchment Areas in Michigan, 2005. 









MRSA Prevalence per 
100,000 population 
(95% Confidence Intervals)* 
Southeast suburb 202 215,769 94 (85-109) 
Southwest 262 133,765 196 (185-223) 
West side 586 363,602 161 (148-167) 
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Background: This report compares the clinical characteristics, epidemiologic 
investigations, infection control evaluations, and microbiologic findings of all seven of 
the cases of vancomycin-resistant Staphylococcus aureus (VRSA) infection in the United 
States during the period 2002-2006. 
Methods: Epidemiologic, clinical, and infection control information was 
collected. VRSA isolates underwent confirmatory identification, antimicrobial 
susceptibility testing, pulsed-field gel electrophoresis, and typing of the resistance genes. 
To assess VRSA transmission, case-patients and their contacts were screened for VRSA 
carriage. 
Results: Seven cases were identified from 2002 through 2006; five were reported 
from Michigan, one was reported from Pennsylvania, and one was reported from New 
York. All VRSA isolates were vanA-positive and had a median vancomycin minimum 
inhibitory concentration of 512 µg/mL. All case patients had a history of prior 
methicillin-resistant S. aureus and enterococcal infection or colonization; all had several 
underlying conditions, including chronic skin ulcers; and most had received vancomycin 





identified beyond any of the case-patients. Infection control precautions were evaluated 
and were consistent with established guidelines. 
Conclusions: Seven patients with vanA-positive VRSA have been identified in the 
United States. Prompt detection by microbiology laboratories and adherence to 
recommended infection control measures for multidrug-resistant organisms appear to 







Staphylococcus aureus and Enterococcus spp. are gram-positive, human 
commensal bacteria.  S. aureus is commonly found on the skin and in the nares of healthy 
people.  Enterococci are normally present in the human intestines.  Both of these bacteria 
are opportunistic pathogens and have been among the most common causes of 
nosocomial infections [1,2].  During the past two decades these bacteria have developed 
resistance to commonly prescribed antimicrobial agents. Methicillin-resistant S. aureus 
(MRSA) infections first emerged in the U.S. in the 1970s, and by the 1990s MRSA was 
considered endemic in most large urban medical centers [3,4].  Vancomycin-resistant 
enterococci (VRE) were first reported in a U.S. hospital in 1989, and rapidly became a 
common cause of healthcare-associated infections [5-7].  Although vancomycin could no 
longer be used to treat the growing number of VRE infections, it remained the only 
uniformly effective antimicrobial agent to treat the numerous MRSA infections [8-10].  In 
1992, Noble et al. [11] demonstrated that conjugal transfer of the vanA gene, which 
mediates vancomycin resistance, from VRE to MRSA on the skin surface of hairless 
mice could be achieved, creating vancomycin-resistant S. aureus (VRSA).  In an era of 
increasing rates of VRE and MRSA infection, the prospect of this transfer occurring 
spontaneously in vivo was of serious concern.  In 1997, the first vancomycin-
intermediate S. aureus (VISA) infection was reported from Japan [12].  However, the 
mechanism of resistance was not mediated by vanA but rather by a change in cell 
physiology due to genetic mutations and altered expression of certain genes, resulting in a 






In June 2002, the Michigan Department of Community Health reported the first 
clinical case of vanA-mediated VRSA in the world [15,16].  Since then, six additional 
cases have been confirmed by the Centers for Disease Control and Prevention (one case 
each from Pennsylvania and New York and five cases from Michigan) [17-21].  
Information regarding only the first three cases has been published.  This report will 
compare the clinical characteristics, epidemiologic investigations, infection control 
evaluations, and microbiologic findings of all seven documented cases of VRSA 
infection in the world. 
 
Methods 
Patients and Medical History 
A patient with VRSA infection was defined as an individual from whom an S. 
aureus isolate was recovered for which the vancomycin MIC was ≥32 μg/mL before 
2006 and ≥16 μg/mL after the vancomycin breakpoint was changed in 2006 [22-24].  
Information regarding medical history, clinical course, treatment modalities (including 
antimicrobial and surgical therapy), and outcome was obtained through medical record 
review and interviews with patients, close family and friends, and medical personnel. 
Epidemiologic Investigations 
A comprehensive epidemiologic contact investigation was conducted for each 
case-patient with VRSA infection and their contacts. Specimens were collected from the 
nares, axilla, groin, wounds, and rectum of each case-patient to determine both VRSA 
and VRE colonization status.  To assess the extent of transmission beyond the case-





available patient contacts during the period of transmissibility.  This period was defined 
as the time from the last date of culture negative for VRSA through the date that 
appropriate infection control precautions were implemented following the isolation of 
VRSA.  Places where the cases resided or visited within the period of transmissibility 
were identified as facilities where transmission could have occurred.  These facilities 
included patient homes, hospitals, rehabilitation and long-term-care facilities, physician 
offices, dialysis centers, an infusion center, a wound care clinic, and a nail salon.  Patient 
contacts considered to be at risk for transmission included people who had direct physical 
contact with patients, shared the same living space, or had the same healthcare providers 
during the period of transmissibility. Persons who worked in laboratories where VRSA 
organisms were initially identified were also considered to be at risk.  Overall, at-risk 
individuals included physicians, nurses, therapists, other patients, family members, 
friends, laboratory technologists, and a manicurist.  On-going surveillance cultures were 
performed for the case-patients and all individuals who remained at risk because of direct 
patient contact throughout the investigations. 
Infection Control Policies and Procedures 
Infection control policies and procedures were assessed in all healthcare facilities 
where the patients with VRSA had received care during their periods of transmissibility.  
These assessments were conducted through interviews with infection control supervisors, 
review of written procedures, and direct observation of healthcare worker practices. 
Laboratory Procedures 
Isolate identification and antimicrobial susceptibility testing were conducted at 





VRSA isolates were then sent to the Centers for Disease Control and Prevention (Atlanta, 
GA) for further characterization.  Species identification was determined using standard 
biochemical and molecular methods [25].  Antimicrobial susceptibility testing was 
performed using the reference broth microdilution method according to the Clinical and 
Laboratory Standards Institute [22-24].  Genomic DNA from VRSA isolates was isolated 
by the silica-gel membrane method (Qiagen DNeasy) and was used as a template for the 
polymerase chain reaction (PCR) to detect the presence of mecA, vanA, vanB, vanC, and 
vanD [26-28].  Pulsed-field gel electrophoresis (PFGE) was performed using SmaI-
digested DNA from VRSA isolates, and banding patterns were analyzed and classified as 
described elsewhere [29].  All isolates underwent typing of the staphylococcal cassette 




Five (71%) of the seven cases of VRSA infection were reported from Michigan 
(Table 5.1). Four (57%) of the seven case-patients with VRSA infection were female, 
five (71%) were white, and the median age was 58 years [range: 40-78 years]. All seven 
case-patients had a history of previous MRSA and enterococcal (four with VRE) 
infections or colonization.  Most case-patients had several underlying conditions, 
including five patients (71%) with chronic skin ulcers, four (57%) with diabetes, and 
three (43%) with chronic renal failure; two (29%) were considered obese.  One of the 
case-patients (patient 2) had not received vancomycin therapy during the 5 years prior to 





(patient 3), four had received vancomycin for 5-9 weeks in the previous three months, 
and one had intermittently received vancomycin for approximately ten years. VRSA was 
isolated from specimens of either ulcers or wounds for six (86%) of the case-patients and 
from urine specimens from a nephrostomy tube for the other case-patient. In all but one 
case-patient (patient 3), specimen collection was prompted by a wound or ulcer that 
appeared infected or was healing (in patient 5). Enterococcal species were recovered 
from the sites from which specimens were culture positive for VRSA for five of the 
seven case-patients; three of the isolates were VRE. All culture specimens were 
polymicrobial and included a variety of gram-negative organisms. At the time of 
specimen collection, four case-patients (57%) were inpatients, two (29%) were 
outpatients, and one (14%) was a long-term care resident.  Case-patients were observed 
for a median of 10 weeks (range: 5-56 weeks) after initial VRSA isolation.  Follow-up 
was concluded after cultures results remained negative for VRSA for at least three 
consecutive weeks without antimicrobial therapy, when the culture site healed, or at the 
time of death. One case-patient persistently tested positive for VRSA, and six case-
patients became culture-negative for VRSA following multimodal therapy, including 
wound-care (n=6), surgical intervention (n=5), and antimicrobial therapy (n=5).  
Epidemiologic Investigation Results 
Two case-patients were colonized with VRSA at body sites other than the initial 
culture sites; one case-patient (patient 5) had VRSA isolated from a specimen from the 
groin, adjacent to the VRSA-infected wound site, and one case-patient (patient 6) had 
VRSA isolated from a specimen from the nares. After showering with chlorhexidine for 





VRSA was not recovered again from either site. VRE isolates (five E. faecalis and one E. 
faecium, one patient was colonized with both) were recovered from specimens from a 
wound, nephrostomy tube, or gastrointestinal tract for five (71%) of the case-patients. 
The median number of case-patient contacts from whom surveillance cultures for 
VRSA were performed was 42 (range: 23-371 case-patient contacts) (Table 5.2).  
Fourteen percent to 30% of case-patient contacts were colonized with methicillin-
susceptible S. aureus (MSSA), 3%-8% were colonized with MRSA, but none were 
colonized with VRSA. 
Infection Control Findings 
Standard infection control precautions were in place at all of the involved 
healthcare facilities prior to identification of the cases of VRSA infection, and the 
policies and practices were appropriate for the respective settings.  Prior to recovery of 
VRSA, most case-patients had known MRSA infection or colonization; therefore, contact 
precautions were being used.  Once VRSA was identified, contact precautions were 
reinforced and some enhanced measures were instituted at all facilities and for all staff 
having continued contact with the infected patients.  For inpatients, the enhanced 
precautions included placing case-patients in private rooms.  For outpatients, treatment 
was administered in dedicated rooms or areas separate from other patients and during the 
last appointment of the day. For all patients, enhanced measures included dedicated staff 
and equipment, new gloves and gowns for each patient interaction, masks with eye 
protection when the potential for splashing/spraying of infectious material existed (e.g., 
during wound care in the podiatry clinic for patient 1), and thoroughly cleaning and 





hospital.  Enhanced contact precautions remained in place throughout the follow-up 
period for both inpatients and outpatients.  Follow-up was discontinued if culture results 
remained negative for VRSA for at least three consecutive weeks without antimicrobial 
therapy or the primary culture site healed.  However, contact precautions remained in 
place if outpatient care continued. 
Laboratory Results 
The seven VRSA isolates had a median vancomycin MIC of 512 µg/mL [range: 
32 to 1024 μg/mL] (Table 5.3). All isolates tested susceptible to five or more 
antimicrobial agents approved by the Food and Drug Administration (FDA) for treating 
S. aureus infection including linezolid, quinupristin/dalfopristin , and 
trimethoprim/sulfamethoxazole; six isolates were susceptible to daptomycin.  All of the 
isolates acquired a vanA-containing Tn1546-like element by independent genetic events 
[15,21,31].  In each isolate the vanA gene was localized to a plasmid, which ranged in 
size from 40 to 120 kb.  Five isolates belonged to MRSA lineage USA100 and contained 
SCCmec type II and one belonged to MRSA lineage USA800 and contained SCCmec 
type IV.  The VRSA isolate from patient 6 did not belong to any current PFGE type in 
the database, and the SCCmec type could not be determined using standard primers.  
 
Discussion 
This report describes the clinical and laboratory characteristics of seven patients 
from whom vanA-containing VRSA isolates were recovered. Most of these patients had 
several characteristics in common including chronic underlying conditions, history of 





two patients had VRE recovered at the time of VRSA isolation, either from the culture 
site or a rectal specimen.  One of the two patients that did not present with VRE infection 
or colonization at the time when VRSA was identified did have a history of cultures 
positive for VRE; the other patient had a history of cultures positive for Enterococcus 
species, but unfortunately, susceptibility testing was never conducted.  It is thought that, 
in all instances, VRE strains likely donated the vanA gene to S. aureus strains within a 
polymicrobial biofilm (e.g., wound, nephrostomy tube, or gastrointestinal tract) [15,21].  
The transferred vanA gene was able to be maintained in the S. aureus strains, even 
without the continued presence of VRE and vancomycin.  
Although most of the case-patients exhibited superficial signs of infection at the 
culture sites, none developed systemic signs or symptoms. This lack of systemic 
involvement may explain the low attributable morbidity and mortality. However, a recent 
study by Fox et al. [32] demonstrated these strains were highly virulent in an 
experimental endocarditis rabbit model, have the ability to cause significant disease, and 
should be treated promptly when isolated.  Currently, not enough data are available to 
recommend a standard treatment regimen for VRSA infection.  All of the VRSA isolates 
were susceptible to a number of FDA-approved antimicrobial agents, and a recent study 
of experimental endocarditis using the first Michigan VRSA strain and a recent in vitro 
study using the VRSA strain from New York suggest that therapy with a synergistic 
combination of vancomycin plus a β-lactam may be an option [32,33].  In addition to the 
variety of antimicrobials used as therapies for the VRSA infections, it is notable that 






Although researchers have been unable to demonstrate in vitro transfer of vanA 
from the VRE strains obtained from these VRSA case-patients to S. aureus strains, 
conjugal transfer of vanA plasmid from VRSA strains to vanA-negative S. aureus strains 
has been demonstrated [15].  This suggests that, once the initial conjugal transfer of vanA 
from VRE strains to S. aureus strains occurs, the spread of vanA between S. aureus 
strains might be more likely. Therefore, to ensure implementation of infection control 
precautions to prevent transmission, clinical microbiology laboratories need to issue 
prompt notification of a potential VRSA isolate to infection control personnel [34,35].  In 
addition, the extent of transmission that could occur before infection control precautions 
are implemented should be assessed. Guidance has been developed to assist in 
developing a plan for this contact investigation [35].  To date, no transmission of VRSA 
beyond any of the case-patients reported here has been identified.  
One of the most prominent, outstanding questions is why five of the seven cases 
of VRSA infection occurred in Michigan. This regional emergence likely occurred 
because of the convergence of several factors, including population characteristics, 
antimicrobial pressure, and the presence of VRE strains that are more likely to donate 
vanA operon. Michigan has a large population of individuals with chronic underlying 
conditions, such as diabetes and end-stage renal disease, both of which are conditions that 
appear associated with these infections. It is estimated that 590,000 adults (7.8% of the 
adult population) in Michigan have received diagnoses of diabetes [36].  Often patients 
with diabetes develop other chronic health conditions, including impaired sensation in the 
feet, leading to unrecognized injuries (such as foot ulcers) from which VRSA has been 





Compared with other states, Michigan has the eighth highest prevalence of diabetes, the 
ninth highest incidence of end-stage renal disease, and the ninth greatest number of 
dialysis and transplant facilities [37].  Patients receiving dialysis are at high risk for 
infection with invasive MRSA, leading to increased vancomycin exposure and, because 
of their reduced renal clearance of the drug, prolonged exposure to subtherapeutic levels 
of vancomycin.  A recent report noted that the rate of invasive MRSA infections among 
patients receiving dialysis is higher than that among any other known patient population 
and is 100 times higher than that among the general population [38].  In addition to these 
patient population factors, Michigan was one of the first locations in the United States to 
document MRSA occurring outside of healthcare facilities in the 1980s [39].  Therefore, 
the early use of vancomycin in Michigan for treatment of these MRSA infections may 
have provided increased selective pressure for the development of vancomycin-resistant 
organisms.  
The demographic characteristics and risk factors of Michigan’s population may 
favor the emergence of VRSA, yet other regions have similar populations and have not 
witnessed this emergence. Therefore, specific characteristics of either the S. aureus or 
VRE strains circulating in Michigan may lead to a greater propensity for them to donate 
and/or acquire vanA. While each VRSA strain has been distinct, the associated VRE 
strains from the Michigan patients contain a broad host-range Inc-18 conjugative plasmid 
that may be more likely to donate vanA to other bacterial species, compared with VRE 
strains from other regions [31,40].  Studies are currently underway to examine the 





In summary, VRSA infection continues to be a rare occurrence. A few specific 
existing factors seem to have predisposed these case-patients to VRSA infection, 
including prior MRSA and enterococcal infections or colonization, underlying conditions 
(such as chronic skin ulcers and diabetes), and previous treatment with vancomycin.  
Further studies are necessary to investigate the specific characteristics of the S. aureus 
and VRE plasmids isolated from these case-patients. Appropriate antimicrobial 
prescribing by healthcare providers, adherence to recommended infection control 
guidelines, and ultimately, the control of both MRSA and VRE are necessary to prevent 
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Abbreviations are as follows: DAP, daptomycin; ETP, ertapenem; LEV, levofloxacin; LNZ, linezolid; PTZ, piperacillin-tazobactam; 
RIF, rifampin; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin; UTIs, urinary tract infections; SOB, shortness of breath; 





Table 5.2. Contact Investigation Results of Vancomycin-Resistant Staphylococcus aureus Cases from the United States, 
2002-2006. 




1 June 2002 MI 371 82 (22%) 28 (8%) 
2 Sept. 2002 PA 262 74 (28%) 21 (8%) 
3 March 2004 NY 101 NA NA 
4 Feb. 2005 MI 35 5 (14%) 1 (3%) 
5 Oct. 2005 MI 23 NA 
[7 (30%) S. aureus]* 
NA 
6 Dec. 2005 MI 42 10 (24%) 2 (5%) 
7 Oct. 2006 MI 38 6 (16%) 2 (5%) 138
 
Abbreviations are as follows: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus. 








Table 5.3. Laboratory Aspects of Vancomycin-Resistant Staphylococcus aureus Infections in Patients from the United States, 2002-
2006. 
Minimum Inhibitory Concentration, µg/ml 
 (Interpretation) Case PFT SCCmec 
CC DAP ERY GM OXA LEV LNZ PEN Q/D RIF SXT TEC TET VAN 
1 USA100 II >8 (R)  0.5 (S) >8 (R) 64 (R) >16 (R) 16 (R) 2 (S) >2 (R) ≤1(S) >8 (R) 0.25 (S) 32 (R) 1(S) 1024 (R) 
2 USA100 II >8 (R) 0.5 (S) >8 (R) 64 (R) >16 (R) 16 (R) 2 (S) >2 (R) ≤1 (S) ≤0.25 (S) 0.25 (S) 8 (S) >16 (R) 32 (R) 
3 USA800 IV >8 (R) 0.5 (S) >8 (R) 32 (R) >16 (R) 16 (R) 2 (S) >2 (R) ≤1 (S) ≤0.25 (S) 0.25 (S) 16 (I) >16 (R) 64 (R) 
4 USA100 II >16 (R) ≤0.5 (S) >8 (R) ≤2 (S) >16 (R) >16 (R) 2 (S) ≥2 (R) 0.5 (S) ≤0.5 (S) 0.25 (S) 16 (I) ≤1(S) 256 (R) 





>16 (R) 1 (S) >8 (R) ≤2 (S) >16 (R) >16 (R) 2 (S) >2 (R) 1 (S) ≤0.5 (S) 0.25 (S) 16 (I) ≤1(S) 1024 (R) 
7 USA100 II >16 (R) 2 (NS) >8 (R) ≤2 (S) >16 (R) 8 (R) 2 (S) >2 (R) 0.5 (S) ≤0.5 (S) 0.25 (S) 16 (I) ≤1(S) 512 (R) 
 
Abbreviations are as follows: PFT, pulsed-field type; SCCmec, staphylococcal cassette chromosome mec; CC, clindamycin; DAP, 
daptomycin; ERY, erythromycin; GM, gentamicin; OXA, oxacillin, LEV, levofloxacin; LNZ, linezolid, PEN, penicillin; Q/D, 
quinupristin-dalfopristin; SXT, trimethoprim/sulfamethoxazole; TEC, teicoplanin, TET, tetracycline, VAN, vancomycin; S, 
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 The research for this dissertation used MRSA infection surveillance data collected 
by MDCH from October 1, 2004 through December 31, 2005 and VRSA data collected 
during investigations of the first seven cases in the nation.  The goal of the first study was 
to assess the comparability when MRSA infections were categorized as HA or CA by 
three commonly used classification schemes: healthcare risk factor, infection type, and 
susceptibility pattern.  All three classification methods appeared to be accurate and 
interchangeable to define MRSA infections, based on the distributions of descriptive 
variables within the HA and CA categories for each of the three classification schemes.  
These distributions were consistent with those seen in previously published literature, 
according to the differing presentations of HA- and CA-MRSA.  Individuals with HA-
MRSA are generally older, have chronic underlying illnesses, and require more frequent 
interactions with healthcare facilities, all of which predispose them to more serious and 
resistant infections.  Individuals with CA-MRSA are, in general, otherwise healthy.  They 
are usually not predisposed by age or underlying illness to these infections, but by 
specific activities and community interactions that place them at an increased risk for 
acquisition, including but not limited to close contact sports, congregate living and daily 




                                                                                                                             
                        
 The comparative analysis revealed concordance across all three classifications for 
only 975 (45%) of the cases; 897 (42%) of the cases were consistently defined as HA or 
CA based on two of the classifications, but not the third.  The remaining 279 (13%) cases 
were missing data that prevented comparison of all three classification methods.  These 
results indicated that the classification of a case as HA or CA was dependent on the 
method chosen.  Each of the three classification methods was inconsistent with the other 
two, for a number of cases, so it was not possible to identify one method as the most 
accurate.  These noted inconsistencies are somewhat inherent, because each classification 
scheme defines an MRSA infection using a different characteristic; one considers 
healthcare interactions of the patient, the second the presentation of infection, and the 
third the genetic makeup of the pathogen.  Each piece of information is important, but 
when considered in isolation does not present a full picture.  Considering the three 
characteristics together would provide a more complete picture of the MRSA infection; 
how it was acquired, how it presented, and the specific makeup of the pathogen. 
These results suggested that further investigation was needed and analyses should 
be conducted to search for a more reliable combination of variables that could be used to 
classify MRSA infection as either HA or CA.  Development of a new model was initiated 
to assess the contribution to the PFGE categorization of the three currently utilized 
classification schemes of healthcare risk factor, infection type, and susceptibility pattern, 
plus other variables including age, hospitalization, survival, and preexisting illnesses. 
 The second study strived to improve the categorization of MRSA infections as 
healthcare- or community-associated using multivariable statistical methods, in contrast 




                                                                                                                             
                        
infection type, or susceptibility pattern.  This research used a subset of cases defined as 
HA or CA by PFGE result.  A variety of analyses were used including: 
sensitivity/specificity and predictive value calculations, logistic regression modeling, 
receiver operating characteristic (ROC) curves, and discriminant analysis. 
A number of variables were considered in the development of the new model to 
more accurately classify MRSA infections as HA or CA, using PFGE result as a gold 
standard for comparison.  Four variables were chosen for the final model, and three of the 
seven tested variables were eliminated during the analytic selection process.  Two of the 
classification variables, infection type and susceptibility pattern, were selected along with 
age and hospitalized for inclusion in this new model.  The existing differences between 
the HA and CA groups for each of these four selected variables, along with the high 
likelihood that the easily obtained data is accurate, makes them strong contributors to the 
new categorization model.  The preexisting illnesses variable and the healthcare risk 
factor classification variable were most likely eliminated because is it generally difficult 
to consistently obtain an accurate history on patients.  In addition, as the prevalence of 
CA-MRSA in the community setting continues to increase, an individual with healthcare 
risk factors could be at greater risk for acquisition of CA-MRSA from their community 
than risk for acquisition of HA-MRSA from the healthcare settings with which they 
interact.  The survival variable (died during time of MRSA infection) was most likely 
eliminated because only a small number of all MRSA infections die and often deaths 
attributed to MRSA are not coded accurately. 
The new proposed statistical model identified a combination of basic variables 




                                                                                                                             
                        
that would likely improve on the accuracy of categorizing MRSA infections in and 
outside of Michigan. 
The third study produced the first epidemiologic profile of MRSA infections in 
the state of Michigan, and demonstrated the discordance between PFGE result reflecting 
historic HA/CA distribution and healthcare risk factor reflecting current location of 
acquisition.  The surveillance data were collected from a variety of locations including 
urban, suburban, and rural areas, as well as a number of settings including hospitals, 
outpatient clinics, long-term care and rehabilitation facilities, correctional facilities, and 
local health departments.  Therefore, it provided a general representation of the entire 
Michigan population, and allowed for the broad characterization of HA- and CA-MRSA 
infections in this state.  The infections reported through the Michigan MRSA 
surveillance, with no data missing for critical variables, were categorized as HA or CA by 
PFGE result if available, or by using the newly developed multivariable statistical model, 
which predicts the HA/CA classification by considering the type of infection caused by 
the MRSA organism, the susceptibility pattern of the MRSA organism, the age of the 
patient, and whether the patient was hospitalized during the MRSA infection. 
Results from this investigation highlighted the significant disease burden that the 
community infections place on the emergency departments and possibly on inpatient 
units of healthcare facilities, which present an increased likelihood for transmission of 
CA-MRSA within healthcare settings.  Correctional facilities were also revealed as 
settings with high burden of CA-MRSA infections, which contribute to transmission in 




                                                                                                                             
                        
individuals between these two settings, and transmission of CA-MRSA to and within 
healthcare facilities as inmates and newly released individuals utilize medical services. 
The differences in variable distributions between HA and CA categorizations by 
the multivariable model Predict result versus healthcare risk factor classification variable 
were evaluated.  The findings identified a group of individuals mostly misclassified due 
to missing healthcare risk factor data or due to a history of hospitalization in the previous 
year.  Categorization based only on the healthcare risk factor scheme misclassified this 
specific group of cases.  The results from the discordant categorizations indicate that the 
model appears more consistent and accurate in classifying this group of cases.  These 
results underscored some important messages; individuals in Michigan may be more 
likely to acquire CA-MRSA from their community than HA-MRSA from brief 
interactions with healthcare facilities, acquisition of CA-MRSA from interactions with 
healthcare facilities may be possible, and the new multivariable classification model is an 
accurate method of classifying HA- and CA-MRSA infections.  The information from the 
new model will help identify where an infection was most likely acquired, as long as the 
delineation remains between the common settings for HA- and CA-MRSA.  This 
information is pertinent to appropriately target control and prevention efforts. 
Reasonable next steps would be to rerun the analyses used in the development of 
the multivariable classification model with a larger, updated Michigan dataset for 
validation, and with datasets from other states and possibly a national MRSA dataset to 
determine whether it is appropriate for areas outside of Michigan.  Quickly knowing 
which type of MRSA is causing an infection provides greater opportunity for the most 




                                                                                                                             
                        
transmission.  This is crucial to successful prevention programs aimed at controlling 
increasing resistance and spread of MRSA. 
The fourth and final investigation described the clinical and laboratory 
characteristics of the first seven patients from whom vanA-containing VRSA isolates 
were recovered. Most of these patients had several characteristics in common including 
chronic underlying conditions, history of MRSA and VRE infection or colonization, and 
previous exposure to vancomycin.  It is thought that, in all instances, VRE strains likely 
donated the vanA gene to S. aureus strains within a polymicrobial biofilm (e.g., wound, 
nephrostomy tube, or gastrointestinal tract).  The transferred vanA gene was able to be 
maintained in the S. aureus strains, even without the continued presence of VRE and 
vancomycin. 
Although most of the case-patients exhibited superficial signs of infection at the 
culture sites, none developed systemic signs or symptoms. This lack of systemic 
involvement may explain the low attributable morbidity and mortality.  All of the VRSA 
isolates were susceptible to a number of FDA-approved antimicrobial agents.  In addition 
to the variety of antimicrobials used as therapies for the VRSA infections, it is notable 
that surgical debridement and wound care were important treatment modalities in this 
case series. 
Conjugal transfer of vanA plasmid from VRSA strains to vanA-negative S. aureus 
strains has been demonstrated.  This suggests that, once the initial conjugal transfer of 
vanA from VRE strains to S. aureus strains occurs, the spread of vanA between S. aureus 
strains might be more likely. Therefore, to ensure implementation of infection control 




                                                                                                                             
                        
prompt notification of a potential VRSA isolate to infection control personnel.  To date, 
no transmission of VRSA beyond any of the case-patients reported here has been 
identified.  
One of the most prominent, outstanding questions is why five of the seven 
original cases, plus two more recent additional cases, of VRSA infection occurred in 
Michigan. This regional emergence likely occurred because of the convergence of several 
factors, including population characteristics, antimicrobial pressure, and the presence of 
VRE strains that are more likely to donate vanA operon.  While each VRSA strain has 
been distinct, the associated VRE strains from the Michigan patients contain a broad 
host-range Inc-18 conjugative plasmid that may be more likely to donate vanA to other 
bacterial species, compared with VRE strains from other regions.  Future studies will 
examine the prevalence of these plasmids within enterococcal isolates from Michigan and 
nationally. 
VRSA infections continue to emerge, though as a rare occurrence.  Further studies 
are necessary to investigate the specific characteristics of the S. aureus and VRE 
plasmids isolated from these case-patients. Appropriate antimicrobial prescribing by 
healthcare providers, adherence to recommended infection control guidelines, and 
ultimately, the control of both MRSA and VRE are necessary to prevent an increase in 
emergence of VRSA strains. 
In summary, the first portion of this research used Michigan MRSA infection 
surveillance data to identify classification inconsistencies from three methods that are 
commonly used to categorize MRSA infections as healthcare- or community-associated.  




                                                                                                                             
                        
was proven to more accurately classify MRSA cases as HA or CA.   Findings from the 
classification of Michigan MRSA infections using the new multivariable model indicate 
that CA-MRSA places a significant disease burden on healthcare and correctional 
facilities in the state.  The final portion of this research used VRSA case data and 
emphasized the seriousness of increasing resistance among HA-MRSA organisms, 
especially in Michigan.  The research for this dissertation has shown that the resistant S. 
aureus profile continues to evolve, and control efforts and educational prevention 
messages must keep up with the changing epidemiology, to effectively combat these 
adept organisms.  To this end, it is crucial that public health efforts to track and 




                                                                                                                             
                        
Appendix. Michigan Department of Community Health Methicillin-Resistant 





                                                                                                                             
                        
 
  
 
153
